prompt
stringlengths 1.92k
9.98k
| response
stringlengths 714
11k
|
|---|---|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-430
Date of Submission: 2024-10-18
This report was submitted by a Nurse from Tran Ltd Medical Center concerning patient ANON-PX-4480. The subject is a 71-year-old other with a significant medical history including coronary artery disease, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 370mg, initiated on 2024-09-14 for Hypothyroidism and discontinued on 2024-10-11; Atorvastatin (Statin) administered via the Oral route at a dosage of 491mg, initiated on 2024-09-14 for Hypercholesterolemia and discontinued on 2024-10-11.
On approximately 2024-10-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Anaphylaxis, Hepatotoxicity, Stevens-Johnson syndrome. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed prevent and advised second. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed this and advised put. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed state and advised chance. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Family bag character pretty. Thus me some seek true while start start. Western environment report stock until event.</data>
|
report_id: ADR-2024-430
report_date: '2024-10-18'
patient_details:
patient_id: ANON-PX-4480
gender: Other
relevant_history:
- coronary artery disease
- chronic kidney disease
age_at_reaction: 71
suspected_drugs:
- drug_name: Levothyroxine
dosage: 370mg
route_of_administration: Oral
start_date: '2024-09-14'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-10-11'
- drug_name: Atorvastatin
dosage: 491mg
route_of_administration: Oral
start_date: '2024-09-14'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-10-11'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2024-10-10'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed prevent and advised second.
- symptom_name: Anaphylaxis
onset_date: '2024-10-10'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed this and advised put.
- symptom_name: Hepatotoxicity
onset_date: '2024-10-10'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed state and advised chance.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-10-10'
severity: Moderate
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Tran Ltd Medical Center
reporter_type: Nurse
notes: Family bag character pretty. Thus me some seek true while start start. Western
environment report stock until event.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-216
Date of Submission: 2025-07-28
This report was submitted by a Other Healthcare Professional from Baker-Moon Medical Center concerning patient ANON-PX-6756. The subject is a 33-year-old other with a significant medical history including coronary artery disease, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 379mg, initiated on 2025-05-28 for Hypertension with the course ongoing.
On approximately 2025-07-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Angioedema. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed eight and advised month. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-216
report_date: '2025-07-28'
patient_details:
patient_id: ANON-PX-6756
gender: Other
relevant_history:
- coronary artery disease
- osteoarthritis
age_at_reaction: 33
suspected_drugs:
- drug_name: Lisinopril
dosage: 379mg
route_of_administration: Subcutaneous
start_date: '2025-05-28'
indication_for_use: Hypertension
drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-07-18'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-07-18'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed eight and advised month.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 6
reporting_facility: Baker-Moon Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-744
Date of Submission: 2024-08-22
This report was submitted by a Physician from Jones LLC Medical Center concerning patient ANON-PX-4769. The subject is a 48-year-old female with a significant medical history including asthma, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intramuscular route at a dosage of 354mg, initiated on 2024-08-09 for Thromboembolism prevention with the course ongoing; Atorvastatin (Statin) administered via the Intramuscular route at a dosage of 401mg, initiated on 2024-08-09 for Hypercholesterolemia with the course ongoing.
On approximately 2024-08-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Somnolence, Angioedema, Anaphylaxis, Headache. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed player and advised country. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed west and advised reality. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Ahead human still model. Go great successful serve.</data>
|
report_id: ADR-2024-744
report_date: '2024-08-22'
patient_details:
patient_id: ANON-PX-4769
gender: Female
relevant_history:
- asthma
- migraines
age_at_reaction: 48
suspected_drugs:
- drug_name: Warfarin
dosage: 354mg
route_of_administration: Intramuscular
start_date: '2024-08-09'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
- drug_name: Atorvastatin
dosage: 401mg
route_of_administration: Intramuscular
start_date: '2024-08-09'
indication_for_use: Hypercholesterolemia
drug_class: Statin
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-08-18'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-08-18'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-08-18'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-08-18'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed player and advised country.
- symptom_name: Headache
onset_date: '2024-08-18'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed west and advised reality.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 5
reporting_facility: Jones LLC Medical Center
reporter_type: Physician
notes: Ahead human still model. Go great successful serve.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-439
Date of Submission: 2025-08-06
This report was submitted by a Physician from Cummings, Buck and Small Medical Center concerning patient ANON-PX-6778. The subject is an adult male with a significant medical history including type 2 diabetes, seasonal allergies, chronic kidney disease, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 204mg, initiated on 2025-05-13 for Bacterial infection and discontinued on 2025-08-03.
On approximately 2025-07-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Diarrhea, Vomiting. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Style surface image television perform. Piece painting class. Million south fall end response hard.</data>
|
report_id: ADR-2025-439
report_date: '2025-08-06'
patient_details:
patient_id: ANON-PX-6778
gender: Male
relevant_history:
- type 2 diabetes
- seasonal allergies
- chronic kidney disease
- osteoarthritis
suspected_drugs:
- drug_name: Amoxicillin
dosage: 204mg
route_of_administration: Intravenous
start_date: '2025-05-13'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-08-03'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-07-21'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-07-21'
severity: Moderate
outcome: Not Recovered
intervention_required: true
- symptom_name: Vomiting
onset_date: '2025-07-21'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 10
reporting_facility: Cummings, Buck and Small Medical Center
reporter_type: Physician
notes: Style surface image television perform. Piece painting class. Million south
fall end response hard.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-729
Date of Submission: 2024-09-27
This report was submitted by a Nurse from Blake, Lopez and Alvarez Medical Center concerning patient ANON-PX-1843. The subject is a 31-year-old other with a significant medical history including type 2 diabetes, coronary artery disease, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 480mg, initiated on 2024-08-20 for Hypothyroidism with the course ongoing; Ibuprofen (NSAID) administered via the Topical route at a dosage of 442mg, initiated on 2024-08-20 for Pain and inflammation with the course ongoing.
On approximately 2024-09-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Pruritus, Hepatotoxicity, Angioedema, Somnolence. The Vomiting was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed soon and advised court. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed will and advised one. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed agency and advised attention. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-729
report_date: '2024-09-27'
patient_details:
patient_id: ANON-PX-1843
gender: Other
relevant_history:
- type 2 diabetes
- coronary artery disease
- hypertension
age_at_reaction: 31
suspected_drugs:
- drug_name: Levothyroxine
dosage: 480mg
route_of_administration: Intramuscular
start_date: '2024-08-20'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
- drug_name: Ibuprofen
dosage: 442mg
route_of_administration: Topical
start_date: '2024-08-20'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-09-05'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed soon and advised court.
- symptom_name: Pruritus
onset_date: '2024-09-05'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-09-05'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed will and advised one.
- symptom_name: Angioedema
onset_date: '2024-09-05'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed agency and advised attention.
- symptom_name: Somnolence
onset_date: '2024-09-05'
severity: Life-threatening
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 9
reporting_facility: Blake, Lopez and Alvarez Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-267
Date of Submission: 2025-06-01
This report was submitted by a Patient from Rojas, Berry and Powell Medical Center concerning patient ANON-PX-1720. The subject is a 54-year-old female with a significant medical history including seasonal allergies, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 399mg, initiated on 2025-04-13 for Thromboembolism prevention with the course ongoing; Omeprazole administered via the Oral route at a dosage of 27mg, initiated on 2025-04-13 for Gastroesophageal reflux disease with the course ongoing.
On approximately 2025-04-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Diarrhea, Pruritus. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed white and advised know. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Score which ago economic. Peace continue find American. Process suddenly develop early. Suddenly card learn money event next local.</data>
|
report_id: ADR-2025-267
report_date: '2025-06-01'
patient_details:
patient_id: ANON-PX-1720
gender: Female
relevant_history:
- seasonal allergies
- anxiety
age_at_reaction: 54
suspected_drugs:
- drug_name: Warfarin
dosage: 399mg
route_of_administration: Subcutaneous
start_date: '2025-04-13'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
- drug_name: Omeprazole
dosage: 27mg
route_of_administration: Oral
start_date: '2025-04-13'
indication_for_use: Gastroesophageal reflux disease
adverse_reactions:
- symptom_name: Headache
onset_date: '2025-04-26'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-04-26'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed white and advised know.
- symptom_name: Pruritus
onset_date: '2025-04-26'
severity: Severe
outcome: Not Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 3
reporting_facility: Rojas, Berry and Powell Medical Center
reporter_type: Patient
notes: Score which ago economic. Peace continue find American. Process suddenly develop
early. Suddenly card learn money event next local.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-674
Date of Submission: 2024-12-22
This report was submitted by a Other Healthcare Professional from Larson, Smith and Mcpherson Medical Center concerning patient ANON-PX-8485. The subject is a 61-year-old male with a significant medical history including type 2 diabetes, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 332mg, initiated on 2024-12-11 for Thromboembolism prevention with the course ongoing.
On approximately 2024-12-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Maculopapular Rash, Vomiting, Angioedema. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed here and advised all. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Speak far father music nature. Next clear size story fall line hit call. Easy than along walk keep life black.</data>
|
report_id: ADR-2024-674
report_date: '2024-12-22'
patient_details:
patient_id: ANON-PX-8485
gender: Male
relevant_history:
- type 2 diabetes
- coronary artery disease
age_at_reaction: 61
suspected_drugs:
- drug_name: Warfarin
dosage: 332mg
route_of_administration: Intravenous
start_date: '2024-12-11'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-12-17'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-17'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed here and advised all.
- symptom_name: Vomiting
onset_date: '2024-12-17'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-12-17'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 4
reporting_facility: Larson, Smith and Mcpherson Medical Center
reporter_type: Other Healthcare Professional
notes: Speak far father music nature. Next clear size story fall line hit call. Easy
than along walk keep life black.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-202
Date of Submission: 2024-12-30
This report was submitted by a Physician from King-Smith Medical Center concerning patient ANON-PX-1649. The subject is a 19-year-old female with a significant medical history including type 2 diabetes, seasonal allergies, asthma, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 377mg, initiated on 2024-10-04 for Hypothyroidism and discontinued on 2024-11-30.
On approximately 2024-11-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Hepatotoxicity, Maculopapular Rash. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Cut run own fast population. Sense allow either you event measure third at.</data>
|
report_id: ADR-2024-202
report_date: '2024-12-30'
patient_details:
patient_id: ANON-PX-1649
gender: Female
relevant_history:
- type 2 diabetes
- seasonal allergies
- asthma
- chronic kidney disease
age_at_reaction: 19
suspected_drugs:
- drug_name: Levothyroxine
dosage: 377mg
route_of_administration: Oral
start_date: '2024-10-04'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-11-30'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-18'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-11-18'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-11-18'
severity: Moderate
outcome: Recovering
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: King-Smith Medical Center
reporter_type: Physician
notes: Cut run own fast population. Sense allow either you event measure third at.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-916
Date of Submission: 2024-12-18
This report was submitted by a Nurse from Joseph Inc Medical Center concerning patient ANON-PX-4197. The subject is a 67-year-old female with a significant medical history including osteoarthritis, anxiety, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin administered via the Subcutaneous route at a dosage of 222mg, initiated on 2024-09-20 for Thromboembolism prevention and discontinued on 2024-12-16.
On approximately 2024-12-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Hepatotoxicity, Angioedema, Somnolence. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Music house else cultural experience age child. Shake gun company imagine term candidate.</data>
|
report_id: ADR-2024-916
report_date: '2024-12-18'
patient_details:
patient_id: ANON-PX-4197
gender: Female
relevant_history:
- osteoarthritis
- anxiety
- type 2 diabetes
age_at_reaction: 67
suspected_drugs:
- drug_name: Warfarin
dosage: 222mg
route_of_administration: Subcutaneous
start_date: '2024-09-20'
indication_for_use: Thromboembolism prevention
end_date: '2024-12-16'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-12-10'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-12-10'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-12-10'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-12-10'
severity: Life-threatening
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 9
reporting_facility: Joseph Inc Medical Center
reporter_type: Nurse
notes: Music house else cultural experience age child. Shake gun company imagine term
candidate.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-184
Date of Submission: 2024-11-24
This report was submitted by a Physician from Collins-Dawson Medical Center concerning patient ANON-PX-7749. The subject is a 63-year-old other with a significant medical history including anxiety, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intravenous route at a dosage of 57mg, initiated on 2024-10-05 for Pain and inflammation and discontinued on 2024-11-16.
On approximately 2024-11-14, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Maculopapular Rash, Nausea. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed discussion and advised sound. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Send positive and between necessary Congress they. Close right because his budget foreign very.</data>
|
report_id: ADR-2024-184
report_date: '2024-11-24'
patient_details:
patient_id: ANON-PX-7749
gender: Other
relevant_history:
- anxiety
- atrial fibrillation
age_at_reaction: 63
suspected_drugs:
- drug_name: Ibuprofen
dosage: 57mg
route_of_administration: Intravenous
start_date: '2024-10-05'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-11-16'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-11-14'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed discussion and advised sound.
- symptom_name: Maculopapular Rash
onset_date: '2024-11-14'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-11-14'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 2
reporting_facility: Collins-Dawson Medical Center
reporter_type: Physician
notes: Send positive and between necessary Congress they. Close right because his
budget foreign very.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-960
Date of Submission: 2025-06-25
This report was submitted by a Nurse from Fisher PLC Medical Center concerning patient ANON-PX-6876. The subject is an adult female with a significant medical history including osteoarthritis, chronic kidney disease, atrial fibrillation, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin administered via the Oral route at a dosage of 247mg, initiated on 2025-06-09 for Type 2 diabetes and discontinued on 2025-06-22.
On approximately 2025-06-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Vomiting, Anaphylaxis. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed security and advised be. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed example and advised truth. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Course not research let week difficult. Large fund spring might. Community each material strong lot attack will.</data>
|
report_id: ADR-2025-960
report_date: '2025-06-25'
patient_details:
patient_id: ANON-PX-6876
gender: Female
relevant_history:
- osteoarthritis
- chronic kidney disease
- atrial fibrillation
- migraines
suspected_drugs:
- drug_name: Metformin
dosage: 247mg
route_of_administration: Oral
start_date: '2025-06-09'
indication_for_use: Type 2 diabetes
end_date: '2025-06-22'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-06-18'
severity: Severe
outcome: Recovered
intervention_required: true
- symptom_name: Vomiting
onset_date: '2025-06-18'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed security and advised be.
- symptom_name: Anaphylaxis
onset_date: '2025-06-18'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed example and advised truth.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 1
reporting_facility: Fisher PLC Medical Center
reporter_type: Nurse
notes: Course not research let week difficult. Large fund spring might. Community
each material strong lot attack will.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-872
Date of Submission: 2025-07-29
This report was submitted by a Patient from Calderon, Lopez and Jackson Medical Center concerning patient ANON-PX-2576. The subject is an adult female with a significant medical history including chronic kidney disease, hypertension, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin administered via the Topical route at a dosage of 102mg, initiated on 2025-06-22 for Neuropathic pain and discontinued on 2025-07-02; Sertraline (SSRI) administered via the Intramuscular route at a dosage of 469mg, initiated on 2025-06-22 for Major depressive disorder and discontinued on 2025-07-02.
On approximately 2025-06-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Dizziness. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed name and advised catch. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-872
report_date: '2025-07-29'
patient_details:
patient_id: ANON-PX-2576
gender: Female
relevant_history:
- chronic kidney disease
- hypertension
- asthma
suspected_drugs:
- drug_name: Gabapentin
dosage: 102mg
route_of_administration: Topical
start_date: '2025-06-22'
indication_for_use: Neuropathic pain
end_date: '2025-07-02'
- drug_name: Sertraline
dosage: 469mg
route_of_administration: Intramuscular
start_date: '2025-06-22'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-07-02'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-06-29'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed name and advised catch.
- symptom_name: Dizziness
onset_date: '2025-06-29'
severity: Moderate
outcome: Not Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Calderon, Lopez and Jackson Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-496
Date of Submission: 2025-05-05
This report was submitted by a Physician from Gordon, Luna and Barrett Medical Center concerning patient ANON-PX-2273. The subject is a 53-year-old other with a significant medical history including migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Oral route at a dosage of 160mg, initiated on 2025-02-20 for Hypercholesterolemia and discontinued on 2025-04-15.
On approximately 2025-03-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Anaphylaxis, Diarrhea, Vomiting. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Small fast civil president shake course good. Process peace determine realize fly.</data>
|
report_id: ADR-2025-496
report_date: '2025-05-05'
patient_details:
patient_id: ANON-PX-2273
gender: Other
relevant_history:
- migraines
- seasonal allergies
age_at_reaction: 53
suspected_drugs:
- drug_name: Atorvastatin
dosage: 160mg
route_of_administration: Oral
start_date: '2025-02-20'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-04-15'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-03-17'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-03-17'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2025-03-17'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-03-17'
severity: Life-threatening
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Gordon, Luna and Barrett Medical Center
reporter_type: Physician
notes: Small fast civil president shake course good. Process peace determine realize
fly.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-396
Date of Submission: 2025-06-28
This report was submitted by a Patient from Mcintyre LLC Medical Center concerning patient ANON-PX-5354. The subject is a 18-year-old female with a significant medical history including atrial fibrillation, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Topical route at a dosage of 360mg, initiated on 2025-06-03 for Type 2 diabetes with the course ongoing; Gabapentin administered via the Subcutaneous route at a dosage of 359mg, initiated on 2025-06-03 for Neuropathic pain with the course ongoing.
On approximately 2025-06-26, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed throughout and advised within. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-396
report_date: '2025-06-28'
patient_details:
patient_id: ANON-PX-5354
gender: Female
relevant_history:
- atrial fibrillation
- coronary artery disease
age_at_reaction: 18
suspected_drugs:
- drug_name: Metformin
dosage: 360mg
route_of_administration: Topical
start_date: '2025-06-03'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
- drug_name: Gabapentin
dosage: 359mg
route_of_administration: Subcutaneous
start_date: '2025-06-03'
indication_for_use: Neuropathic pain
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-06-26'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed throughout and advised within.
- symptom_name: Headache
onset_date: '2025-06-26'
severity: Severe
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 9
reporting_facility: Mcintyre LLC Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-790
Date of Submission: 2024-09-24
This report was submitted by a Physician from Kim-Martin Medical Center concerning patient ANON-PX-3241. The subject is a 60-year-old male with a significant medical history including seasonal allergies, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 475mg, initiated on 2024-07-27 for Hypothyroidism with the course ongoing.
On approximately 2024-08-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Angioedema. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed first and advised month. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed light and advised including. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Effect seat character serious sit rather run blood. How movement vote dinner training. He forget natural rise. Unit before act dark of one.</data>
|
report_id: ADR-2024-790
report_date: '2024-09-24'
patient_details:
patient_id: ANON-PX-3241
gender: Male
relevant_history:
- seasonal allergies
- chronic kidney disease
age_at_reaction: 60
suspected_drugs:
- drug_name: Levothyroxine
dosage: 475mg
route_of_administration: Oral
start_date: '2024-07-27'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2024-08-02'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed first and advised month.
- symptom_name: Angioedema
onset_date: '2024-08-02'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed light and advised including.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Kim-Martin Medical Center
reporter_type: Physician
notes: Effect seat character serious sit rather run blood. How movement vote dinner
training. He forget natural rise. Unit before act dark of one.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-805
Date of Submission: 2024-12-25
This report was submitted by a Patient from Miller-White Medical Center concerning patient ANON-PX-6098. The subject is a 71-year-old female with a significant medical history including osteoarthritis, anxiety, coronary artery disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline administered via the Oral route at a dosage of 415mg, initiated on 2024-10-17 for Major depressive disorder and discontinued on 2024-12-02; Warfarin administered via the Subcutaneous route at a dosage of 367mg, initiated on 2024-10-17 for Thromboembolism prevention and discontinued on 2024-12-02.
On approximately 2024-10-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Stevens-Johnson syndrome, Hepatotoxicity, Maculopapular Rash, Diarrhea. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed none and advised own. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed itself and advised single. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-805
report_date: '2024-12-25'
patient_details:
patient_id: ANON-PX-6098
gender: Female
relevant_history:
- osteoarthritis
- anxiety
- coronary artery disease
- atrial fibrillation
age_at_reaction: 71
suspected_drugs:
- drug_name: Sertraline
dosage: 415mg
route_of_administration: Oral
start_date: '2024-10-17'
indication_for_use: Major depressive disorder
end_date: '2024-12-02'
- drug_name: Warfarin
dosage: 367mg
route_of_administration: Subcutaneous
start_date: '2024-10-17'
indication_for_use: Thromboembolism prevention
end_date: '2024-12-02'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-10-30'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-10-30'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-10-30'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed none and advised own.
- symptom_name: Maculopapular Rash
onset_date: '2024-10-30'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-10-30'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed itself and advised single.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 8
reporting_facility: Miller-White Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-693
Date of Submission: 2025-06-27
This report was submitted by a Other Healthcare Professional from Brown Inc Medical Center concerning patient ANON-PX-1786. The subject is a 59-year-old female with a significant medical history including anxiety, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 271mg, initiated on 2025-04-14 for Bacterial infection and discontinued on 2025-06-23; Ibuprofen (NSAID) administered via the Topical route at a dosage of 167mg, initiated on 2025-04-14 for Pain and inflammation and discontinued on 2025-06-23.
On approximately 2025-06-06, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Maculopapular Rash, Pruritus, Anaphylaxis. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed end and advised analysis. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed another and advised baby. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-693
report_date: '2025-06-27'
patient_details:
patient_id: ANON-PX-1786
gender: Female
relevant_history:
- anxiety
- coronary artery disease
age_at_reaction: 59
suspected_drugs:
- drug_name: Amoxicillin
dosage: 271mg
route_of_administration: Intravenous
start_date: '2025-04-14'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-06-23'
- drug_name: Ibuprofen
dosage: 167mg
route_of_administration: Topical
start_date: '2025-04-14'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-06-23'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-06-06'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed end and advised analysis.
- symptom_name: Maculopapular Rash
onset_date: '2025-06-06'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-06-06'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-06-06'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed another and advised baby.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 2
reporting_facility: Brown Inc Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-235
Date of Submission: 2024-09-12
This report was submitted by a Nurse from Miller, Freeman and Baldwin Medical Center concerning patient ANON-PX-4057. The subject is an adult other with a significant medical history including seasonal allergies, coronary artery disease, type 2 diabetes, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Oral route at a dosage of 240mg, initiated on 2024-07-15 for Hypothyroidism and discontinued on 2024-09-06; Metformin (Biguanide) administered via the Intramuscular route at a dosage of 212mg, initiated on 2024-07-15 for Type 2 diabetes and discontinued on 2024-09-06.
On approximately 2024-07-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Nausea, Headache, Anaphylaxis. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed stuff and advised explain. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Around alone both special worker science special. I discussion Republican hotel bar seek.</data>
|
report_id: ADR-2024-235
report_date: '2024-09-12'
patient_details:
patient_id: ANON-PX-4057
gender: Other
relevant_history:
- seasonal allergies
- coronary artery disease
- type 2 diabetes
- osteoarthritis
suspected_drugs:
- drug_name: Levothyroxine
dosage: 240mg
route_of_administration: Oral
start_date: '2024-07-15'
indication_for_use: Hypothyroidism
end_date: '2024-09-06'
- drug_name: Metformin
dosage: 212mg
route_of_administration: Intramuscular
start_date: '2024-07-15'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-09-06'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-07-24'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-07-24'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Headache
onset_date: '2024-07-24'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed stuff and advised explain.
- symptom_name: Anaphylaxis
onset_date: '2024-07-24'
severity: Severe
outcome: Not Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 7
reporting_facility: Miller, Freeman and Baldwin Medical Center
reporter_type: Nurse
notes: Around alone both special worker science special. I discussion Republican hotel
bar seek.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-440
Date of Submission: 2024-10-02
This report was submitted by a Nurse from Clark, Contreras and Smith Medical Center concerning patient ANON-PX-2199. The subject is a 54-year-old other with a significant medical history including hypertension, osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 370mg, initiated on 2024-09-10 for Hypertension and discontinued on 2024-09-25.
On approximately 2024-09-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Vomiting. The Hepatotoxicity was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed treat and advised party. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Than quite any. Color compare member. Force war American majority not federal.</data>
|
report_id: ADR-2024-440
report_date: '2024-10-02'
patient_details:
patient_id: ANON-PX-2199
gender: Other
relevant_history:
- hypertension
- osteoarthritis
- asthma
age_at_reaction: 54
suspected_drugs:
- drug_name: Lisinopril
dosage: 370mg
route_of_administration: Topical
start_date: '2024-09-10'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-09-25'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-09-22'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-09-22'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed treat and advised party.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 2
reporting_facility: Clark, Contreras and Smith Medical Center
reporter_type: Nurse
notes: Than quite any. Color compare member. Force war American majority not federal.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-314
Date of Submission: 2024-12-04
This report was submitted by a Pharmacist from Vincent-Powers Medical Center concerning patient ANON-PX-1806. The subject is an adult female with a significant medical history including chronic kidney disease, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 33mg, initiated on 2024-10-31 for Hypothyroidism with the course ongoing.
On approximately 2024-11-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Somnolence, Anaphylaxis. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed determine and advised more. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Glass since security while simple cut. Each spring exactly. Figure law entire I operation.</data>
|
report_id: ADR-2024-314
report_date: '2024-12-04'
patient_details:
patient_id: ANON-PX-1806
gender: Female
relevant_history:
- chronic kidney disease
- type 2 diabetes
suspected_drugs:
- drug_name: Levothyroxine
dosage: 33mg
route_of_administration: Intravenous
start_date: '2024-10-31'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-25'
severity: Life-threatening
outcome: Unknown
intervention_required: true
- symptom_name: Somnolence
onset_date: '2024-11-25'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-11-25'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed determine and advised more.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Vincent-Powers Medical Center
reporter_type: Pharmacist
notes: Glass since security while simple cut. Each spring exactly. Figure law entire
I operation.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-565
Date of Submission: 2025-06-16
This report was submitted by a Nurse from Hammond, Lamb and Krause Medical Center concerning patient ANON-PX-6112. The subject is a 82-year-old other with a significant medical history including osteoarthritis, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 305mg, initiated on 2025-04-19 for Hypertension and discontinued on 2025-05-08.
On approximately 2025-04-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Nausea, Hepatotoxicity, Pruritus, Anaphylaxis. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed make and advised forward. The current patient status regarding this symptom is 'Recovering'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed particular and advised hard. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Financial might board quickly test.</data>
|
report_id: ADR-2025-565
report_date: '2025-06-16'
patient_details:
patient_id: ANON-PX-6112
gender: Other
relevant_history:
- osteoarthritis
- chronic kidney disease
age_at_reaction: 82
suspected_drugs:
- drug_name: Lisinopril
dosage: 305mg
route_of_administration: Topical
start_date: '2025-04-19'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-05-08'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-27'
severity: Severe
outcome: Recovering
intervention_required: true
- symptom_name: Nausea
onset_date: '2025-04-27'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-04-27'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed make and advised forward.
- symptom_name: Pruritus
onset_date: '2025-04-27'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
- symptom_name: Anaphylaxis
onset_date: '2025-04-27'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed particular and advised hard.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Hammond, Lamb and Krause Medical Center
reporter_type: Nurse
notes: Financial might board quickly test.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-933
Date of Submission: 2025-06-22
This report was submitted by a Nurse from Brooks-Adkins Medical Center concerning patient ANON-PX-9102. The subject is a 43-year-old female with a significant medical history including anxiety, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Topical route at a dosage of 393mg, initiated on 2025-05-20 for Hypercholesterolemia and discontinued on 2025-06-20.
On approximately 2025-06-19, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Anaphylaxis, Pruritus. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed amount and advised door. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed beyond and advised later. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Security fast gas hard material able player. Question employee professor finish. Suggest seem talk box southern summer community maintain.</data>
|
report_id: ADR-2025-933
report_date: '2025-06-22'
patient_details:
patient_id: ANON-PX-9102
gender: Female
relevant_history:
- anxiety
- seasonal allergies
age_at_reaction: 43
suspected_drugs:
- drug_name: Atorvastatin
dosage: 393mg
route_of_administration: Topical
start_date: '2025-05-20'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-06-20'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2025-06-19'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-06-19'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed amount and advised door.
- symptom_name: Pruritus
onset_date: '2025-06-19'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed beyond and advised later.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 10
reporting_facility: Brooks-Adkins Medical Center
reporter_type: Nurse
notes: Security fast gas hard material able player. Question employee professor finish.
Suggest seem talk box southern summer community maintain.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-895
Date of Submission: 2025-04-16
This report was submitted by a Other Healthcare Professional from Wolfe-Taylor Medical Center concerning patient ANON-PX-1721. The subject is an adult male with a significant medical history including anxiety, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline administered via the Intravenous route at a dosage of 136mg, initiated on 2025-04-05 for Major depressive disorder and discontinued on 2025-04-13; Warfarin (Anticoagulant) administered via the Oral route at a dosage of 474mg, initiated on 2025-04-05 for Thromboembolism prevention and discontinued on 2025-04-13.
On approximately 2025-04-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Stevens-Johnson syndrome, Nausea. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed exist and advised answer. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed letter and advised thing. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Color look pattern catch federal. Wonder fill small from protect some social. Strong professor herself fast heart any.</data>
|
report_id: ADR-2025-895
report_date: '2025-04-16'
patient_details:
patient_id: ANON-PX-1721
gender: Male
relevant_history:
- anxiety
- coronary artery disease
suspected_drugs:
- drug_name: Sertraline
dosage: 136mg
route_of_administration: Intravenous
start_date: '2025-04-05'
indication_for_use: Major depressive disorder
end_date: '2025-04-13'
- drug_name: Warfarin
dosage: 474mg
route_of_administration: Oral
start_date: '2025-04-05'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-04-13'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-04-10'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed exist and advised answer.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-10'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed letter and advised thing.
- symptom_name: Nausea
onset_date: '2025-04-10'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 4
reporting_facility: Wolfe-Taylor Medical Center
reporter_type: Other Healthcare Professional
notes: Color look pattern catch federal. Wonder fill small from protect some social.
Strong professor herself fast heart any.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-708
Date of Submission: 2025-08-03
This report was submitted by a Physician from Edwards-Dennis Medical Center concerning patient ANON-PX-7311. The subject is a 81-year-old female with a significant medical history including coronary artery disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 55mg, initiated on 2025-05-14 for Hypercholesterolemia and discontinued on 2025-07-04; Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 371mg, initiated on 2025-05-14 for Hypertension and discontinued on 2025-07-04.
On approximately 2025-06-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Hepatotoxicity. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed who and advised rule. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Into occur hear stock me. Could arrive animal film. Never prepare add yourself human exist center.</data>
|
report_id: ADR-2025-708
report_date: '2025-08-03'
patient_details:
patient_id: ANON-PX-7311
gender: Female
relevant_history:
- coronary artery disease
- migraines
age_at_reaction: 81
suspected_drugs:
- drug_name: Atorvastatin
dosage: 55mg
route_of_administration: Subcutaneous
start_date: '2025-05-14'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-07-04'
- drug_name: Lisinopril
dosage: 371mg
route_of_administration: Topical
start_date: '2025-05-14'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-07-04'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-06-25'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-06-25'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed who and advised rule.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 7
reporting_facility: Edwards-Dennis Medical Center
reporter_type: Physician
notes: Into occur hear stock me. Could arrive animal film. Never prepare add yourself
human exist center.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-848
Date of Submission: 2024-10-13
This report was submitted by a Other Healthcare Professional from White-Harmon Medical Center concerning patient ANON-PX-3377. The subject is a 34-year-old other with a significant medical history including coronary artery disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline administered via the Oral route at a dosage of 155mg, initiated on 2024-08-20 for Major depressive disorder and discontinued on 2024-09-17.
On approximately 2024-08-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Angioedema, Stevens-Johnson syndrome, Nausea. The Somnolence was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed role and advised member. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed gas and advised you. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Mention court degree as western boy. Whole score public institution prevent fall. Job skin manager admit street. Wear very reduce.</data>
|
report_id: ADR-2024-848
report_date: '2024-10-13'
patient_details:
patient_id: ANON-PX-3377
gender: Other
relevant_history:
- coronary artery disease
- anxiety
age_at_reaction: 34
suspected_drugs:
- drug_name: Sertraline
dosage: 155mg
route_of_administration: Oral
start_date: '2024-08-20'
indication_for_use: Major depressive disorder
end_date: '2024-09-17'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2024-08-23'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-08-23'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed role and advised member.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-08-23'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-08-23'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed gas and advised you.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 1
reporting_facility: White-Harmon Medical Center
reporter_type: Other Healthcare Professional
notes: Mention court degree as western boy. Whole score public institution prevent
fall. Job skin manager admit street. Wear very reduce.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-609
Date of Submission: 2024-10-31
This report was submitted by a Patient from Page Group Medical Center concerning patient ANON-PX-1233. The subject is an adult other with a significant medical history including migraines, asthma, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 415mg, initiated on 2024-10-20 for Pain and inflammation and discontinued on 2024-10-23.
On approximately 2024-10-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Pruritus. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed despite and advised require. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Rest unit the vote expert oil lose. Heart meeting care soldier also.</data>
|
report_id: ADR-2024-609
report_date: '2024-10-31'
patient_details:
patient_id: ANON-PX-1233
gender: Other
relevant_history:
- migraines
- asthma
- osteoarthritis
suspected_drugs:
- drug_name: Ibuprofen
dosage: 415mg
route_of_administration: Oral
start_date: '2024-10-20'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-10-23'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2024-10-22'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed despite and advised require.
- symptom_name: Pruritus
onset_date: '2024-10-22'
severity: Life-threatening
outcome: Fatal
intervention_required: true
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 10
reporting_facility: Page Group Medical Center
reporter_type: Patient
notes: Rest unit the vote expert oil lose. Heart meeting care soldier also.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-814
Date of Submission: 2025-03-16
This report was submitted by a Patient from Oneal LLC Medical Center concerning patient ANON-PX-9413. The subject is a 85-year-old other with a significant medical history including migraines, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Topical route at a dosage of 327mg, initiated on 2025-03-05 for Hypothyroidism and discontinued on 2025-03-12.
On approximately 2025-03-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Maculopapular Rash, Hepatotoxicity, Nausea. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed laugh and advised play. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed line and advised third. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Describe any south. Camera determine one artist from body sound.</data>
|
report_id: ADR-2025-814
report_date: '2025-03-16'
patient_details:
patient_id: ANON-PX-9413
gender: Other
relevant_history:
- migraines
- atrial fibrillation
age_at_reaction: 85
suspected_drugs:
- drug_name: Levothyroxine
dosage: 327mg
route_of_administration: Topical
start_date: '2025-03-05'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2025-03-12'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2025-03-09'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed laugh and advised play.
- symptom_name: Maculopapular Rash
onset_date: '2025-03-09'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-03-09'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Nausea
onset_date: '2025-03-09'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed line and advised third.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 5
reporting_facility: Oneal LLC Medical Center
reporter_type: Patient
notes: Describe any south. Camera determine one artist from body sound.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-611
Date of Submission: 2025-05-16
This report was submitted by a Other Healthcare Professional from Park-Harrington Medical Center concerning patient ANON-PX-5346. The subject is an adult female with a significant medical history including osteoarthritis, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 144mg, initiated on 2025-03-05 for Pain and inflammation with the course ongoing; Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 174mg, initiated on 2025-03-05 for Hypertension with the course ongoing.
On approximately 2025-03-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Nausea. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed structure and advised Mr. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed left and advised study. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Because score possible they data movement. Dream capital service. Option small trial which blood hour.</data>
|
report_id: ADR-2025-611
report_date: '2025-05-16'
patient_details:
patient_id: ANON-PX-5346
gender: Female
relevant_history:
- osteoarthritis
- coronary artery disease
suspected_drugs:
- drug_name: Ibuprofen
dosage: 144mg
route_of_administration: Oral
start_date: '2025-03-05'
indication_for_use: Pain and inflammation
drug_class: NSAID
- drug_name: Lisinopril
dosage: 174mg
route_of_administration: Oral
start_date: '2025-03-05'
indication_for_use: Hypertension
drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-03-23'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed structure and advised Mr.
- symptom_name: Nausea
onset_date: '2025-03-23'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed left and advised study.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 9
reporting_facility: Park-Harrington Medical Center
reporter_type: Other Healthcare Professional
notes: Because score possible they data movement. Dream capital service. Option small
trial which blood hour.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-218
Date of Submission: 2025-02-20
This report was submitted by a Nurse from Ramirez-Jackson Medical Center concerning patient ANON-PX-1725. The subject is an adult other with a significant medical history including coronary artery disease, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 386mg, initiated on 2024-12-22 for Neuropathic pain with the course ongoing.
On approximately 2025-01-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Nausea, Vomiting. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed human and advised goal. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Rule author huge it risk billion song low. Ok some whatever fast small. Upon fast government various sometimes follow would.</data>
|
report_id: ADR-2025-218
report_date: '2025-02-20'
patient_details:
patient_id: ANON-PX-1725
gender: Other
relevant_history:
- coronary artery disease
- asthma
suspected_drugs:
- drug_name: Gabapentin
dosage: 386mg
route_of_administration: Intravenous
start_date: '2024-12-22'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-01-15'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-01-15'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-01-15'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed human and advised goal.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 5
reporting_facility: Ramirez-Jackson Medical Center
reporter_type: Nurse
notes: Rule author huge it risk billion song low. Ok some whatever fast small. Upon
fast government various sometimes follow would.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-448
Date of Submission: 2024-11-30
This report was submitted by a Pharmacist from Aguilar-Phillips Medical Center concerning patient ANON-PX-1158. The subject is a 58-year-old other with a significant medical history including migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intramuscular route at a dosage of 231mg, initiated on 2024-09-21 for Thromboembolism prevention with the course ongoing; Atorvastatin administered via the Subcutaneous route at a dosage of 195mg, initiated on 2024-09-21 for Hypercholesterolemia with the course ongoing.
On approximately 2024-11-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Vomiting, Somnolence, Nausea, Maculopapular Rash. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed movie and advised off. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Society born a everyone. Might attack quickly certainly. Over address lead worker vote meet risk.</data>
|
report_id: ADR-2024-448
report_date: '2024-11-30'
patient_details:
patient_id: ANON-PX-1158
gender: Other
relevant_history:
- migraines
- type 2 diabetes
age_at_reaction: 58
suspected_drugs:
- drug_name: Warfarin
dosage: 231mg
route_of_administration: Intramuscular
start_date: '2024-09-21'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
- drug_name: Atorvastatin
dosage: 195mg
route_of_administration: Subcutaneous
start_date: '2024-09-21'
indication_for_use: Hypercholesterolemia
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-15'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-11-15'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-11-15'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed movie and advised off.
- symptom_name: Nausea
onset_date: '2024-11-15'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-11-15'
severity: Moderate
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 8
reporting_facility: Aguilar-Phillips Medical Center
reporter_type: Pharmacist
notes: Society born a everyone. Might attack quickly certainly. Over address lead
worker vote meet risk.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-944
Date of Submission: 2025-08-03
This report was submitted by a Physician from Moore and Sons Medical Center concerning patient ANON-PX-2599. The subject is an adult male with a significant medical history including type 2 diabetes, anxiety, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Intramuscular route at a dosage of 43mg, initiated on 2025-06-20 for Neuropathic pain with the course ongoing.
On approximately 2025-06-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Hepatotoxicity, Somnolence, Stevens-Johnson syndrome, Headache. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed house and advised create. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed history and advised thus. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Win fly serious peace. Media true risk training production reduce consider. Happy begin relate.</data>
|
report_id: ADR-2025-944
report_date: '2025-08-03'
patient_details:
patient_id: ANON-PX-2599
gender: Male
relevant_history:
- type 2 diabetes
- anxiety
- osteoarthritis
suspected_drugs:
- drug_name: Gabapentin
dosage: 43mg
route_of_administration: Intramuscular
start_date: '2025-06-20'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-06-27'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2025-06-27'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Somnolence
onset_date: '2025-06-27'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed house and advised create.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-06-27'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed history and advised thus.
- symptom_name: Headache
onset_date: '2025-06-27'
severity: Mild
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 1
reporting_facility: Moore and Sons Medical Center
reporter_type: Physician
notes: Win fly serious peace. Media true risk training production reduce consider.
Happy begin relate.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-184
Date of Submission: 2025-04-06
This report was submitted by a Other Healthcare Professional from Roberson-Davis Medical Center concerning patient ANON-PX-1746. The subject is a 77-year-old male with a significant medical history including chronic kidney disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Topical route at a dosage of 379mg, initiated on 2025-03-26 for Type 2 diabetes and discontinued on 2025-04-04; Atorvastatin (Statin) administered via the Topical route at a dosage of 23mg, initiated on 2025-03-26 for Hypercholesterolemia and discontinued on 2025-04-04.
On approximately 2025-04-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Stevens-Johnson syndrome, Somnolence, Maculopapular Rash, Nausea. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed general and advised statement. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed clearly and advised summer. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed affect and advised of. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Business table left affect sometimes. Thought base former need. Claim laugh since. We receive political call sound home.</data>
|
report_id: ADR-2025-184
report_date: '2025-04-06'
patient_details:
patient_id: ANON-PX-1746
gender: Male
relevant_history:
- chronic kidney disease
- migraines
age_at_reaction: 77
suspected_drugs:
- drug_name: Metformin
dosage: 379mg
route_of_administration: Topical
start_date: '2025-03-26'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-04-04'
- drug_name: Atorvastatin
dosage: 23mg
route_of_administration: Topical
start_date: '2025-03-26'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2025-04-04'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-04-04'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed general and advised statement.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-04'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Somnolence
onset_date: '2025-04-04'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed clearly and advised summer.
- symptom_name: Maculopapular Rash
onset_date: '2025-04-04'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-04-04'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed affect and advised of.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Roberson-Davis Medical Center
reporter_type: Other Healthcare Professional
notes: Business table left affect sometimes. Thought base former need. Claim laugh
since. We receive political call sound home.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-123
Date of Submission: 2025-02-19
This report was submitted by a Physician from Herrera-Pena Medical Center concerning patient ANON-PX-6219. The subject is an adult female with a significant medical history including atrial fibrillation, anxiety, coronary artery disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Oral route at a dosage of 403mg, initiated on 2024-11-27 for Hypercholesterolemia with the course ongoing; Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 84mg, initiated on 2024-11-27 for Neuropathic pain with the course ongoing.
On approximately 2025-01-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Nausea, Anaphylaxis, Dizziness, Headache. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed become and advised sense. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Headache was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-123
report_date: '2025-02-19'
patient_details:
patient_id: ANON-PX-6219
gender: Female
relevant_history:
- atrial fibrillation
- anxiety
- coronary artery disease
- migraines
suspected_drugs:
- drug_name: Atorvastatin
dosage: 403mg
route_of_administration: Oral
start_date: '2024-11-27'
indication_for_use: Hypercholesterolemia
- drug_name: Gabapentin
dosage: 84mg
route_of_administration: Intravenous
start_date: '2024-11-27'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-01-02'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed become and advised sense.
- symptom_name: Nausea
onset_date: '2025-01-02'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-01-02'
severity: Severe
outcome: Fatal
intervention_required: true
- symptom_name: Dizziness
onset_date: '2025-01-02'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Headache
onset_date: '2025-01-02'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Herrera-Pena Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-897
Date of Submission: 2025-01-21
This report was submitted by a Nurse from Carr, Gordon and Mitchell Medical Center concerning patient ANON-PX-7372. The subject is a 61-year-old male with a significant medical history including coronary artery disease, asthma, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine administered via the Intramuscular route at a dosage of 375mg, initiated on 2024-11-26 for Hypothyroidism and discontinued on 2024-12-15; Amoxicillin administered via the Intravenous route at a dosage of 47mg, initiated on 2024-11-26 for Bacterial infection and discontinued on 2024-12-15.
On approximately 2024-12-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Somnolence, Anaphylaxis. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed social and advised account. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Difference remember nearly report program. Sport Congress again her. Today shake national send oil.</data>
|
report_id: ADR-2025-897
report_date: '2025-01-21'
patient_details:
patient_id: ANON-PX-7372
gender: Male
relevant_history:
- coronary artery disease
- asthma
- osteoarthritis
age_at_reaction: 61
suspected_drugs:
- drug_name: Levothyroxine
dosage: 375mg
route_of_administration: Intramuscular
start_date: '2024-11-26'
indication_for_use: Hypothyroidism
end_date: '2024-12-15'
- drug_name: Amoxicillin
dosage: 47mg
route_of_administration: Intravenous
start_date: '2024-11-26'
indication_for_use: Bacterial infection
end_date: '2024-12-15'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-12-09'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-12-09'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed social and advised account.
- symptom_name: Anaphylaxis
onset_date: '2024-12-09'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Carr, Gordon and Mitchell Medical Center
reporter_type: Nurse
notes: Difference remember nearly report program. Sport Congress again her. Today
shake national send oil.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-464
Date of Submission: 2024-09-06
This report was submitted by a Nurse from Graves, Brown and Sullivan Medical Center concerning patient ANON-PX-7831. The subject is a 23-year-old male with a significant medical history including seasonal allergies, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Topical route at a dosage of 148mg, initiated on 2024-08-06 for Neuropathic pain and discontinued on 2024-09-05.
On approximately 2024-08-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Vomiting, Diarrhea. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed series and advised past. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: It bring factor understand score establish power. Know stay Republican reduce purpose material. Church parent eat fire. Save carry whole special.</data>
|
report_id: ADR-2024-464
report_date: '2024-09-06'
patient_details:
patient_id: ANON-PX-7831
gender: Male
relevant_history:
- seasonal allergies
- atrial fibrillation
age_at_reaction: 23
suspected_drugs:
- drug_name: Gabapentin
dosage: 148mg
route_of_administration: Topical
start_date: '2024-08-06'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2024-09-05'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-08-18'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-08-18'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-08-18'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed series and advised past.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 5
reporting_facility: Graves, Brown and Sullivan Medical Center
reporter_type: Nurse
notes: It bring factor understand score establish power. Know stay Republican reduce
purpose material. Church parent eat fire. Save carry whole special.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-931
Date of Submission: 2025-03-21
This report was submitted by a Nurse from Jordan-James Medical Center concerning patient ANON-PX-1076. The subject is an adult other with a significant medical history including type 2 diabetes, osteoarthritis, migraines, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 95mg, initiated on 2025-01-10 for Gastroesophageal reflux disease and discontinued on 2025-02-03.
On approximately 2025-01-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Headache. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Edge development rule may. Short structure record for lawyer fear. Team country will rather.</data>
|
report_id: ADR-2025-931
report_date: '2025-03-21'
patient_details:
patient_id: ANON-PX-1076
gender: Other
relevant_history:
- type 2 diabetes
- osteoarthritis
- migraines
- seasonal allergies
suspected_drugs:
- drug_name: Omeprazole
dosage: 95mg
route_of_administration: Intravenous
start_date: '2025-01-10'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-02-03'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-01-28'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Headache
onset_date: '2025-01-28'
severity: Moderate
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 9
reporting_facility: Jordan-James Medical Center
reporter_type: Nurse
notes: Edge development rule may. Short structure record for lawyer fear. Team country
will rather.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-774
Date of Submission: 2025-07-31
This report was submitted by a Nurse from Vang, Taylor and Romero Medical Center concerning patient ANON-PX-3875. The subject is an adult male with a significant medical history including coronary artery disease, hypertension, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intravenous route at a dosage of 222mg, initiated on 2025-07-12 for Gastroesophageal reflux disease with the course ongoing; Sertraline (SSRI) administered via the Oral route at a dosage of 181mg, initiated on 2025-07-12 for Major depressive disorder with the course ongoing.
On approximately 2025-07-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Headache. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed more and advised hope. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Sit apply group should meeting right red.</data>
|
report_id: ADR-2025-774
report_date: '2025-07-31'
patient_details:
patient_id: ANON-PX-3875
gender: Male
relevant_history:
- coronary artery disease
- hypertension
- seasonal allergies
suspected_drugs:
- drug_name: Omeprazole
dosage: 222mg
route_of_administration: Intravenous
start_date: '2025-07-12'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
- drug_name: Sertraline
dosage: 181mg
route_of_administration: Oral
start_date: '2025-07-12'
indication_for_use: Major depressive disorder
drug_class: SSRI
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-07-27'
severity: Mild
outcome: Recovered
intervention_required: true
- symptom_name: Headache
onset_date: '2025-07-27'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed more and advised hope.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 10
reporting_facility: Vang, Taylor and Romero Medical Center
reporter_type: Nurse
notes: Sit apply group should meeting right red.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-792
Date of Submission: 2024-12-10
This report was submitted by a Other Healthcare Professional from Mayer-Davis Medical Center concerning patient ANON-PX-6843. The subject is an adult other with a significant medical history including osteoarthritis, atrial fibrillation, type 2 diabetes, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 424mg, initiated on 2024-10-28 for Gastroesophageal reflux disease and discontinued on 2024-12-05; Sertraline (SSRI) administered via the Oral route at a dosage of 385mg, initiated on 2024-10-28 for Major depressive disorder and discontinued on 2024-12-05.
On approximately 2024-11-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Angioedema. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed plant and advised gas. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-792
report_date: '2024-12-10'
patient_details:
patient_id: ANON-PX-6843
gender: Other
relevant_history:
- osteoarthritis
- atrial fibrillation
- type 2 diabetes
- hypertension
suspected_drugs:
- drug_name: Omeprazole
dosage: 424mg
route_of_administration: Intramuscular
start_date: '2024-10-28'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-12-05'
- drug_name: Sertraline
dosage: 385mg
route_of_administration: Oral
start_date: '2024-10-28'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2024-12-05'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2024-11-11'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-11-11'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed plant and advised gas.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 3
reporting_facility: Mayer-Davis Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-598
Date of Submission: 2025-02-03
This report was submitted by a Pharmacist from Sherman and Sons Medical Center concerning patient ANON-PX-4626. The subject is an adult male with a significant medical history including osteoarthritis, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole administered via the Oral route at a dosage of 387mg, initiated on 2024-12-08 for Gastroesophageal reflux disease and discontinued on 2025-01-27; Metformin administered via the Oral route at a dosage of 69mg, initiated on 2024-12-08 for Type 2 diabetes and discontinued on 2025-01-27.
On approximately 2025-01-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Angioedema, Stevens-Johnson syndrome, Somnolence. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Send include tough minute somebody attorney. Road some more past affect head street.</data>
|
report_id: ADR-2025-598
report_date: '2025-02-03'
patient_details:
patient_id: ANON-PX-4626
gender: Male
relevant_history:
- osteoarthritis
- chronic kidney disease
suspected_drugs:
- drug_name: Omeprazole
dosage: 387mg
route_of_administration: Oral
start_date: '2024-12-08'
indication_for_use: Gastroesophageal reflux disease
end_date: '2025-01-27'
- drug_name: Metformin
dosage: 69mg
route_of_administration: Oral
start_date: '2024-12-08'
indication_for_use: Type 2 diabetes
end_date: '2025-01-27'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-01-02'
severity: Life-threatening
outcome: Recovering
intervention_required: true
- symptom_name: Angioedema
onset_date: '2025-01-02'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-01-02'
severity: Severe
outcome: Recovering
intervention_required: true
- symptom_name: Somnolence
onset_date: '2025-01-02'
severity: Mild
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Sherman and Sons Medical Center
reporter_type: Pharmacist
notes: Send include tough minute somebody attorney. Road some more past affect head
street.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-537
Date of Submission: 2025-02-16
This report was submitted by a Nurse from Hatfield and Sons Medical Center concerning patient ANON-PX-5930. The subject is an adult female with a significant medical history including seasonal allergies, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Intramuscular route at a dosage of 485mg, initiated on 2024-12-30 for Hypertension and discontinued on 2025-02-04.
On approximately 2025-01-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Hepatotoxicity. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed court and advised authority. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed interest and advised thought. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-537
report_date: '2025-02-16'
patient_details:
patient_id: ANON-PX-5930
gender: Female
relevant_history:
- seasonal allergies
- atrial fibrillation
suspected_drugs:
- drug_name: Lisinopril
dosage: 485mg
route_of_administration: Intramuscular
start_date: '2024-12-30'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-02-04'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-01-21'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed court and advised authority.
- symptom_name: Hepatotoxicity
onset_date: '2025-01-21'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed interest and advised thought.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 4
reporting_facility: Hatfield and Sons Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-773
Date of Submission: 2024-10-13
This report was submitted by a Pharmacist from Hubbard-Rodriguez Medical Center concerning patient ANON-PX-8935. The subject is an adult female with a significant medical history including osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Topical route at a dosage of 477mg, initiated on 2024-07-20 for Gastroesophageal reflux disease and discontinued on 2024-08-19.
On approximately 2024-08-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Maculopapular Rash, Vomiting, Pruritus, Angioedema. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed material and advised both. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed nearly and advised federal. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed southern and advised food. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed ever and advised central. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Mean above interesting world reduce way. Here seven specific peace important. Woman town product.</data>
|
report_id: ADR-2024-773
report_date: '2024-10-13'
patient_details:
patient_id: ANON-PX-8935
gender: Female
relevant_history:
- osteoarthritis
- asthma
suspected_drugs:
- drug_name: Omeprazole
dosage: 477mg
route_of_administration: Topical
start_date: '2024-07-20'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2024-08-19'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2024-08-12'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-08-12'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed material and advised both.
- symptom_name: Vomiting
onset_date: '2024-08-12'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed nearly and advised federal.
- symptom_name: Pruritus
onset_date: '2024-08-12'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed southern and advised food.
- symptom_name: Angioedema
onset_date: '2024-08-12'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed ever and advised central.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 4
reporting_facility: Hubbard-Rodriguez Medical Center
reporter_type: Pharmacist
notes: Mean above interesting world reduce way. Here seven specific peace important.
Woman town product.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-622
Date of Submission: 2025-04-24
This report was submitted by a Pharmacist from Peters-Hansen Medical Center concerning patient ANON-PX-3537. The subject is a 90-year-old male with a significant medical history including seasonal allergies, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 281mg, initiated on 2025-03-22 for Hypertension and discontinued on 2025-04-06; Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 233mg, initiated on 2025-03-22 for Gastroesophageal reflux disease and discontinued on 2025-04-06.
On approximately 2025-03-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Headache, Maculopapular Rash, Angioedema. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed I and advised crime. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Clearly nor church suddenly. Themselves manager local option team my deep. Ahead himself open keep gas most.</data>
|
report_id: ADR-2025-622
report_date: '2025-04-24'
patient_details:
patient_id: ANON-PX-3537
gender: Male
relevant_history:
- seasonal allergies
- hypertension
age_at_reaction: 90
suspected_drugs:
- drug_name: Lisinopril
dosage: 281mg
route_of_administration: Topical
start_date: '2025-03-22'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-04-06'
- drug_name: Omeprazole
dosage: 233mg
route_of_administration: Subcutaneous
start_date: '2025-03-22'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-04-06'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-03-29'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Headache
onset_date: '2025-03-29'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed I and advised crime.
- symptom_name: Maculopapular Rash
onset_date: '2025-03-29'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-03-29'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 8
reporting_facility: Peters-Hansen Medical Center
reporter_type: Pharmacist
notes: Clearly nor church suddenly. Themselves manager local option team my deep.
Ahead himself open keep gas most.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-946
Date of Submission: 2024-11-13
This report was submitted by a Pharmacist from Stewart Ltd Medical Center concerning patient ANON-PX-9059. The subject is a 49-year-old female with a significant medical history including osteoarthritis, seasonal allergies, chronic kidney disease, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intravenous route at a dosage of 124mg, initiated on 2024-10-13 for Pain and inflammation with the course ongoing.
On approximately 2024-10-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Somnolence, Hepatotoxicity. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed house and advised kid. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-946
report_date: '2024-11-13'
patient_details:
patient_id: ANON-PX-9059
gender: Female
relevant_history:
- osteoarthritis
- seasonal allergies
- chronic kidney disease
- hypertension
age_at_reaction: 49
suspected_drugs:
- drug_name: Ibuprofen
dosage: 124mg
route_of_administration: Intravenous
start_date: '2024-10-13'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-10-27'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed house and advised kid.
- symptom_name: Somnolence
onset_date: '2024-10-27'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-10-27'
severity: Life-threatening
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Stewart Ltd Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-789
Date of Submission: 2025-04-06
This report was submitted by a Physician from Skinner, Franklin and Hayes Medical Center concerning patient ANON-PX-2941. The subject is a 32-year-old other with a significant medical history including coronary artery disease, atrial fibrillation, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin administered via the Oral route at a dosage of 385mg, initiated on 2025-03-29 for Neuropathic pain and discontinued on 2025-04-02; Levothyroxine administered via the Intravenous route at a dosage of 330mg, initiated on 2025-03-29 for Hypothyroidism and discontinued on 2025-04-02.
On approximately 2025-03-31, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Dizziness, Nausea. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Whole imagine young large. Great few make very side. Five beyond choose them.</data>
|
report_id: ADR-2025-789
report_date: '2025-04-06'
patient_details:
patient_id: ANON-PX-2941
gender: Other
relevant_history:
- coronary artery disease
- atrial fibrillation
- anxiety
age_at_reaction: 32
suspected_drugs:
- drug_name: Gabapentin
dosage: 385mg
route_of_administration: Oral
start_date: '2025-03-29'
indication_for_use: Neuropathic pain
end_date: '2025-04-02'
- drug_name: Levothyroxine
dosage: 330mg
route_of_administration: Intravenous
start_date: '2025-03-29'
indication_for_use: Hypothyroidism
end_date: '2025-04-02'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-03-31'
severity: Severe
outcome: Not Recovered
intervention_required: true
- symptom_name: Dizziness
onset_date: '2025-03-31'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-03-31'
severity: Moderate
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Skinner, Franklin and Hayes Medical Center
reporter_type: Physician
notes: Whole imagine young large. Great few make very side. Five beyond choose them.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-970
Date of Submission: 2024-11-12
This report was submitted by a Nurse from Hamilton, Young and Sharp Medical Center concerning patient ANON-PX-6916. The subject is an adult female with a significant medical history including coronary artery disease, type 2 diabetes, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Topical route at a dosage of 65mg, initiated on 2024-09-10 for Hypercholesterolemia with the course ongoing; Metformin administered via the Topical route at a dosage of 274mg, initiated on 2024-09-10 for Type 2 diabetes with the course ongoing.
On approximately 2024-09-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Dizziness, Vomiting, Diarrhea. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed fire and advised particularly. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed respond and advised reason. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Idea daughter Mrs. Support design true art.</data>
|
report_id: ADR-2024-970
report_date: '2024-11-12'
patient_details:
patient_id: ANON-PX-6916
gender: Female
relevant_history:
- coronary artery disease
- type 2 diabetes
- osteoarthritis
suspected_drugs:
- drug_name: Atorvastatin
dosage: 65mg
route_of_administration: Topical
start_date: '2024-09-10'
indication_for_use: Hypercholesterolemia
drug_class: Statin
- drug_name: Metformin
dosage: 274mg
route_of_administration: Topical
start_date: '2024-09-10'
indication_for_use: Type 2 diabetes
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-09-21'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed fire and advised particularly.
- symptom_name: Dizziness
onset_date: '2024-09-21'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed respond and advised reason.
- symptom_name: Vomiting
onset_date: '2024-09-21'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-09-21'
severity: Mild
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 10
reporting_facility: Hamilton, Young and Sharp Medical Center
reporter_type: Nurse
notes: Idea daughter Mrs. Support design true art.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-723
Date of Submission: 2025-08-11
This report was submitted by a Physician from Vargas-Gonzalez Medical Center concerning patient ANON-PX-5009. The subject is a 29-year-old other with a significant medical history including type 2 diabetes, migraines, osteoarthritis, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intravenous route at a dosage of 399mg, initiated on 2025-05-26 for Hypertension with the course ongoing.
On approximately 2025-05-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Diarrhea. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed day and advised pass. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-723
report_date: '2025-08-11'
patient_details:
patient_id: ANON-PX-5009
gender: Other
relevant_history:
- type 2 diabetes
- migraines
- osteoarthritis
- atrial fibrillation
age_at_reaction: 29
suspected_drugs:
- drug_name: Lisinopril
dosage: 399mg
route_of_administration: Intravenous
start_date: '2025-05-26'
indication_for_use: Hypertension
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-05-29'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed day and advised pass.
- symptom_name: Diarrhea
onset_date: '2025-05-29'
severity: Moderate
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Vargas-Gonzalez Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-382
Date of Submission: 2025-01-09
This report was submitted by a Physician from Moss, Ward and Peterson Medical Center concerning patient ANON-PX-2107. The subject is a 41-year-old other with a significant medical history including type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Intravenous route at a dosage of 334mg, initiated on 2024-11-14 for Hypertension and discontinued on 2025-01-03.
On approximately 2024-12-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Diarrhea, Nausea, Maculopapular Rash, Anaphylaxis. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-382
report_date: '2025-01-09'
patient_details:
patient_id: ANON-PX-2107
gender: Other
relevant_history:
- type 2 diabetes
- migraines
age_at_reaction: 41
suspected_drugs:
- drug_name: Lisinopril
dosage: 334mg
route_of_administration: Intravenous
start_date: '2024-11-14'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-01-03'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2024-12-25'
severity: Severe
outcome: Unknown
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2024-12-25'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-12-25'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-25'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-12-25'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 4
reporting_facility: Moss, Ward and Peterson Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-331
Date of Submission: 2024-11-26
This report was submitted by a Other Healthcare Professional from Frost-Torres Medical Center concerning patient ANON-PX-2992. The subject is a 46-year-old other with a significant medical history including chronic kidney disease, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Subcutaneous route at a dosage of 300mg, initiated on 2024-09-04 for Pain and inflammation and discontinued on 2024-10-05.
On approximately 2024-09-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Nausea, Maculopapular Rash, Dizziness, Stevens-Johnson syndrome. The Angioedema was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed such and advised nearly. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-331
report_date: '2024-11-26'
patient_details:
patient_id: ANON-PX-2992
gender: Other
relevant_history:
- chronic kidney disease
- osteoarthritis
age_at_reaction: 46
suspected_drugs:
- drug_name: Ibuprofen
dosage: 300mg
route_of_administration: Subcutaneous
start_date: '2024-09-04'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-10-05'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2024-09-07'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-09-07'
severity: Moderate
outcome: Not Recovered
intervention_required: true
- symptom_name: Maculopapular Rash
onset_date: '2024-09-07'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed such and advised nearly.
- symptom_name: Dizziness
onset_date: '2024-09-07'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-07'
severity: Severe
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 1
reporting_facility: Frost-Torres Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-646
Date of Submission: 2024-09-17
This report was submitted by a Pharmacist from Banks Inc Medical Center concerning patient ANON-PX-3924. The subject is an adult male with a significant medical history including migraines, anxiety, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intramuscular route at a dosage of 263mg, initiated on 2024-07-27 for Bacterial infection with the course ongoing.
On approximately 2024-08-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Pruritus. The Nausea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-646
report_date: '2024-09-17'
patient_details:
patient_id: ANON-PX-3924
gender: Male
relevant_history:
- migraines
- anxiety
- asthma
suspected_drugs:
- drug_name: Amoxicillin
dosage: 263mg
route_of_administration: Intramuscular
start_date: '2024-07-27'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-08-24'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-08-24'
severity: Moderate
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Banks Inc Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-101
Date of Submission: 2025-08-09
This report was submitted by a Pharmacist from Boone-King Medical Center concerning patient ANON-PX-8249. The subject is a 77-year-old male with a significant medical history including hypertension, osteoarthritis, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Subcutaneous route at a dosage of 292mg, initiated on 2025-06-10 for Hypothyroidism and discontinued on 2025-08-01; Ibuprofen (NSAID) administered via the Oral route at a dosage of 451mg, initiated on 2025-06-10 for Pain and inflammation and discontinued on 2025-08-01.
On approximately 2025-07-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Stevens-Johnson syndrome, Maculopapular Rash, Somnolence. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed yes and advised eight. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed box and advised find. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed trial and advised establish. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-101
report_date: '2025-08-09'
patient_details:
patient_id: ANON-PX-8249
gender: Male
relevant_history:
- hypertension
- osteoarthritis
- migraines
age_at_reaction: 77
suspected_drugs:
- drug_name: Levothyroxine
dosage: 292mg
route_of_administration: Subcutaneous
start_date: '2025-06-10'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2025-08-01'
- drug_name: Ibuprofen
dosage: 451mg
route_of_administration: Oral
start_date: '2025-06-10'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-08-01'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-07-28'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-07-28'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed yes and advised eight.
- symptom_name: Maculopapular Rash
onset_date: '2025-07-28'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed box and advised find.
- symptom_name: Somnolence
onset_date: '2025-07-28'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed trial and advised establish.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 6
reporting_facility: Boone-King Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-299
Date of Submission: 2024-10-15
This report was submitted by a Patient from Dougherty-Gonzalez Medical Center concerning patient ANON-PX-8756. The subject is a 49-year-old male with a significant medical history including anxiety, asthma, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen administered via the Subcutaneous route at a dosage of 249mg, initiated on 2024-09-13 for Pain and inflammation with the course ongoing; Amoxicillin administered via the Subcutaneous route at a dosage of 251mg, initiated on 2024-09-13 for Bacterial infection with the course ongoing.
On approximately 2024-09-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Maculopapular Rash, Pruritus, Dizziness. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed guy and advised a. The current patient status regarding this symptom is 'Fatal'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-299
report_date: '2024-10-15'
patient_details:
patient_id: ANON-PX-8756
gender: Male
relevant_history:
- anxiety
- asthma
- chronic kidney disease
age_at_reaction: 49
suspected_drugs:
- drug_name: Ibuprofen
dosage: 249mg
route_of_administration: Subcutaneous
start_date: '2024-09-13'
indication_for_use: Pain and inflammation
- drug_name: Amoxicillin
dosage: 251mg
route_of_administration: Subcutaneous
start_date: '2024-09-13'
indication_for_use: Bacterial infection
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-09-25'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed guy and advised a.
- symptom_name: Maculopapular Rash
onset_date: '2024-09-25'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-09-25'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-09-25'
severity: Mild
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 3
reporting_facility: Dougherty-Gonzalez Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-717
Date of Submission: 2025-01-19
This report was submitted by a Pharmacist from Wilkerson, Hale and Smith Medical Center concerning patient ANON-PX-1847. The subject is a 23-year-old other with a significant medical history including coronary artery disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Oral route at a dosage of 327mg, initiated on 2024-12-26 for Major depressive disorder and discontinued on 2025-01-16.
On approximately 2024-12-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Pruritus. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Per western social score.</data>
|
report_id: ADR-2025-717
report_date: '2025-01-19'
patient_details:
patient_id: ANON-PX-1847
gender: Other
relevant_history:
- coronary artery disease
- migraines
age_at_reaction: 23
suspected_drugs:
- drug_name: Sertraline
dosage: 327mg
route_of_administration: Oral
start_date: '2024-12-26'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-01-16'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-12-30'
severity: Moderate
outcome: Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-12-30'
severity: Mild
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Wilkerson, Hale and Smith Medical Center
reporter_type: Pharmacist
notes: Per western social score.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-956
Date of Submission: 2025-06-08
This report was submitted by a Other Healthcare Professional from Jackson and Sons Medical Center concerning patient ANON-PX-6143. The subject is a 24-year-old other with a significant medical history including osteoarthritis, hypertension, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin administered via the Intramuscular route at a dosage of 208mg, initiated on 2025-04-20 for Type 2 diabetes and discontinued on 2025-05-21; Omeprazole (Proton-pump inhibitor) administered via the Oral route at a dosage of 172mg, initiated on 2025-04-20 for Gastroesophageal reflux disease and discontinued on 2025-05-21.
On approximately 2025-05-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Maculopapular Rash. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-956
report_date: '2025-06-08'
patient_details:
patient_id: ANON-PX-6143
gender: Other
relevant_history:
- osteoarthritis
- hypertension
- chronic kidney disease
age_at_reaction: 24
suspected_drugs:
- drug_name: Metformin
dosage: 208mg
route_of_administration: Intramuscular
start_date: '2025-04-20'
indication_for_use: Type 2 diabetes
end_date: '2025-05-21'
- drug_name: Omeprazole
dosage: 172mg
route_of_administration: Oral
start_date: '2025-04-20'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-05-21'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-05-13'
severity: Life-threatening
outcome: Recovering
intervention_required: true
- symptom_name: Maculopapular Rash
onset_date: '2025-05-13'
severity: Life-threatening
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Jackson and Sons Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-321
Date of Submission: 2024-12-05
This report was submitted by a Patient from Nguyen PLC Medical Center concerning patient ANON-PX-1197. The subject is a 30-year-old other with a significant medical history including hypertension, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 466mg, initiated on 2024-10-27 for Thromboembolism prevention and discontinued on 2024-11-20; Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 198mg, initiated on 2024-10-27 for Bacterial infection and discontinued on 2024-11-20.
On approximately 2024-11-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Somnolence, Vomiting. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Including spend wonder data lawyer have understand. Another wish through cultural participant real.</data>
|
report_id: ADR-2024-321
report_date: '2024-12-05'
patient_details:
patient_id: ANON-PX-1197
gender: Other
relevant_history:
- hypertension
- anxiety
age_at_reaction: 30
suspected_drugs:
- drug_name: Warfarin
dosage: 466mg
route_of_administration: Intravenous
start_date: '2024-10-27'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-11-20'
- drug_name: Amoxicillin
dosage: 198mg
route_of_administration: Intravenous
start_date: '2024-10-27'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-11-20'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-11-07'
severity: Moderate
outcome: Recovering
intervention_required: true
- symptom_name: Somnolence
onset_date: '2024-11-07'
severity: Mild
outcome: Recovered
intervention_required: true
- symptom_name: Vomiting
onset_date: '2024-11-07'
severity: Mild
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 9
reporting_facility: Nguyen PLC Medical Center
reporter_type: Patient
notes: Including spend wonder data lawyer have understand. Another wish through cultural
participant real.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-549
Date of Submission: 2024-09-25
This report was submitted by a Other Healthcare Professional from Butler, Novak and James Medical Center concerning patient ANON-PX-5870. The subject is a 52-year-old male with a significant medical history including coronary artery disease, anxiety, hypertension, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Oral route at a dosage of 191mg, initiated on 2024-08-20 for Hypercholesterolemia and discontinued on 2024-09-22.
On approximately 2024-09-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Hepatotoxicity, Headache, Maculopapular Rash. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-549
report_date: '2024-09-25'
patient_details:
patient_id: ANON-PX-5870
gender: Male
relevant_history:
- coronary artery disease
- anxiety
- hypertension
- atrial fibrillation
age_at_reaction: 52
suspected_drugs:
- drug_name: Atorvastatin
dosage: 191mg
route_of_administration: Oral
start_date: '2024-08-20'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-09-22'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2024-09-22'
severity: Life-threatening
outcome: Fatal
intervention_required: true
- symptom_name: Hepatotoxicity
onset_date: '2024-09-22'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Headache
onset_date: '2024-09-22'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Maculopapular Rash
onset_date: '2024-09-22'
severity: Moderate
outcome: Unknown
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 10
reporting_facility: Butler, Novak and James Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-914
Date of Submission: 2025-03-30
This report was submitted by a Pharmacist from Knight Inc Medical Center concerning patient ANON-PX-3217. The subject is an adult male with a significant medical history including seasonal allergies, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intramuscular route at a dosage of 474mg, initiated on 2025-03-15 for Neuropathic pain and discontinued on 2025-03-29.
On approximately 2025-03-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Maculopapular Rash, Somnolence, Stevens-Johnson syndrome, Vomiting. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed approach and advised sit. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed control and advised job. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Accept hit go recent make trouble. Contain away particular about.</data>
|
report_id: ADR-2025-914
report_date: '2025-03-30'
patient_details:
patient_id: ANON-PX-3217
gender: Male
relevant_history:
- seasonal allergies
- migraines
suspected_drugs:
- drug_name: Gabapentin
dosage: 474mg
route_of_administration: Intramuscular
start_date: '2025-03-15'
indication_for_use: Neuropathic pain
end_date: '2025-03-29'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-03-25'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-03-25'
severity: Severe
outcome: Unknown
intervention_required: true
- symptom_name: Somnolence
onset_date: '2025-03-25'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed approach and advised sit.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-03-25'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-03-25'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed control and advised job.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 6
reporting_facility: Knight Inc Medical Center
reporter_type: Pharmacist
notes: Accept hit go recent make trouble. Contain away particular about.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-851
Date of Submission: 2025-08-12
This report was submitted by a Patient from Carter, Hart and Contreras Medical Center concerning patient ANON-PX-1052. The subject is a 59-year-old male with a significant medical history including anxiety, type 2 diabetes, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intramuscular route at a dosage of 41mg, initiated on 2025-05-24 for Type 2 diabetes and discontinued on 2025-07-24; Sertraline (SSRI) administered via the Intramuscular route at a dosage of 438mg, initiated on 2025-05-24 for Major depressive disorder and discontinued on 2025-07-24.
On approximately 2025-07-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Maculopapular Rash, Hepatotoxicity. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed heavy and advised education. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed voice and advised finally. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Economic particularly spend exactly. Lot work choose visit tough find visit. Audience since stop fight happen join enough.</data>
|
report_id: ADR-2025-851
report_date: '2025-08-12'
patient_details:
patient_id: ANON-PX-1052
gender: Male
relevant_history:
- anxiety
- type 2 diabetes
- migraines
age_at_reaction: 59
suspected_drugs:
- drug_name: Metformin
dosage: 41mg
route_of_administration: Intramuscular
start_date: '2025-05-24'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-07-24'
- drug_name: Sertraline
dosage: 438mg
route_of_administration: Intramuscular
start_date: '2025-05-24'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2025-07-24'
adverse_reactions:
- symptom_name: Headache
onset_date: '2025-07-21'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed heavy and advised education.
- symptom_name: Maculopapular Rash
onset_date: '2025-07-21'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed voice and advised finally.
- symptom_name: Hepatotoxicity
onset_date: '2025-07-21'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 3
reporting_facility: Carter, Hart and Contreras Medical Center
reporter_type: Patient
notes: Economic particularly spend exactly. Lot work choose visit tough find visit.
Audience since stop fight happen join enough.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-619
Date of Submission: 2025-01-16
This report was submitted by a Pharmacist from Barrera Inc Medical Center concerning patient ANON-PX-1176. The subject is a 85-year-old female with a significant medical history including asthma, osteoarthritis, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 243mg, initiated on 2024-10-25 for Hypertension and discontinued on 2025-01-09.
On approximately 2024-11-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Vomiting, Stevens-Johnson syndrome, Maculopapular Rash. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed those and advised beyond. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-619
report_date: '2025-01-16'
patient_details:
patient_id: ANON-PX-1176
gender: Female
relevant_history:
- asthma
- osteoarthritis
- seasonal allergies
age_at_reaction: 85
suspected_drugs:
- drug_name: Lisinopril
dosage: 243mg
route_of_administration: Oral
start_date: '2024-10-25'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-01-09'
adverse_reactions:
- symptom_name: Diarrhea
onset_date: '2024-11-11'
severity: Severe
outcome: Fatal
intervention_required: true
- symptom_name: Vomiting
onset_date: '2024-11-11'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed those and advised beyond.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-11-11'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Maculopapular Rash
onset_date: '2024-11-11'
severity: Moderate
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 9
reporting_facility: Barrera Inc Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-771
Date of Submission: 2025-01-02
This report was submitted by a Other Healthcare Professional from Crawford-Cox Medical Center concerning patient ANON-PX-6646. The subject is a 49-year-old female with a significant medical history including atrial fibrillation, chronic kidney disease, osteoarthritis, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Topical route at a dosage of 343mg, initiated on 2024-11-05 for Bacterial infection and discontinued on 2025-01-01.
On approximately 2024-12-18, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Pruritus, Somnolence. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed simple and advised maybe. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed north and advised simple. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Really expert health hot address individual economy. Itself lot everyone stock develop. American kid wait part.</data>
|
report_id: ADR-2025-771
report_date: '2025-01-02'
patient_details:
patient_id: ANON-PX-6646
gender: Female
relevant_history:
- atrial fibrillation
- chronic kidney disease
- osteoarthritis
- hypertension
age_at_reaction: 49
suspected_drugs:
- drug_name: Amoxicillin
dosage: 343mg
route_of_administration: Topical
start_date: '2024-11-05'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-01-01'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-12-18'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed simple and advised maybe.
- symptom_name: Pruritus
onset_date: '2024-12-18'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed north and advised simple.
- symptom_name: Somnolence
onset_date: '2024-12-18'
severity: Mild
outcome: Not Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 2
reporting_facility: Crawford-Cox Medical Center
reporter_type: Other Healthcare Professional
notes: Really expert health hot address individual economy. Itself lot everyone stock
develop. American kid wait part.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-319
Date of Submission: 2024-09-25
This report was submitted by a Patient from Gomez-Guerrero Medical Center concerning patient ANON-PX-3952. The subject is a 84-year-old female with a significant medical history including migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Topical route at a dosage of 373mg, initiated on 2024-08-19 for Hypertension and discontinued on 2024-08-31.
On approximately 2024-08-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Pruritus, Somnolence, Dizziness. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-319
report_date: '2024-09-25'
patient_details:
patient_id: ANON-PX-3952
gender: Female
relevant_history:
- migraines
- type 2 diabetes
age_at_reaction: 84
suspected_drugs:
- drug_name: Lisinopril
dosage: 373mg
route_of_administration: Topical
start_date: '2024-08-19'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2024-08-31'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-08-28'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-08-28'
severity: Severe
outcome: Fatal
intervention_required: true
- symptom_name: Somnolence
onset_date: '2024-08-28'
severity: Moderate
outcome: Recovered
intervention_required: true
- symptom_name: Dizziness
onset_date: '2024-08-28'
severity: Moderate
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Gomez-Guerrero Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-504
Date of Submission: 2025-04-02
This report was submitted by a Nurse from Larsen Ltd Medical Center concerning patient ANON-PX-9101. The subject is an adult female with a significant medical history including anxiety, osteoarthritis, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Intravenous route at a dosage of 336mg, initiated on 2025-03-20 for Type 2 diabetes and discontinued on 2025-04-01.
On approximately 2025-03-30, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Maculopapular Rash. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed simply and advised possible. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-504
report_date: '2025-04-02'
patient_details:
patient_id: ANON-PX-9101
gender: Female
relevant_history:
- anxiety
- osteoarthritis
- chronic kidney disease
suspected_drugs:
- drug_name: Metformin
dosage: 336mg
route_of_administration: Intravenous
start_date: '2025-03-20'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-04-01'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-03-30'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-03-30'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed simply and advised possible.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 8
reporting_facility: Larsen Ltd Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-771
Date of Submission: 2025-03-24
This report was submitted by a Physician from Ellis-Ray Medical Center concerning patient ANON-PX-5681. The subject is a 53-year-old female with a significant medical history including asthma, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Oral route at a dosage of 488mg, initiated on 2025-02-22 for Type 2 diabetes and discontinued on 2025-03-21.
On approximately 2025-03-21, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Diarrhea, Stevens-Johnson syndrome, Maculopapular Rash. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed news and advised spend. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Maculopapular Rash was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-771
report_date: '2025-03-24'
patient_details:
patient_id: ANON-PX-5681
gender: Female
relevant_history:
- asthma
- osteoarthritis
age_at_reaction: 53
suspected_drugs:
- drug_name: Metformin
dosage: 488mg
route_of_administration: Oral
start_date: '2025-02-22'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2025-03-21'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-03-21'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed news and advised spend.
- symptom_name: Diarrhea
onset_date: '2025-03-21'
severity: Mild
outcome: Unknown
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-03-21'
severity: Moderate
outcome: Not Recovered
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2025-03-21'
severity: Severe
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 3
reporting_facility: Ellis-Ray Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-993
Date of Submission: 2024-09-09
This report was submitted by a Nurse from Davis, Dennis and Hardy Medical Center concerning patient ANON-PX-6632. The subject is an adult other with a significant medical history including asthma, type 2 diabetes, hypertension, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 101mg, initiated on 2024-08-10 for Hypercholesterolemia and discontinued on 2024-09-08; Sertraline administered via the Subcutaneous route at a dosage of 33mg, initiated on 2024-08-10 for Major depressive disorder and discontinued on 2024-09-08.
On approximately 2024-09-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Maculopapular Rash, Angioedema. The Stevens-Johnson syndrome was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed manager and advised fish. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed benefit and advised religious. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Level picture from base exist recently including. Congress as time task success nation. Add upon be lot.</data>
|
report_id: ADR-2024-993
report_date: '2024-09-09'
patient_details:
patient_id: ANON-PX-6632
gender: Other
relevant_history:
- asthma
- type 2 diabetes
- hypertension
- seasonal allergies
suspected_drugs:
- drug_name: Atorvastatin
dosage: 101mg
route_of_administration: Subcutaneous
start_date: '2024-08-10'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-09-08'
- drug_name: Sertraline
dosage: 33mg
route_of_administration: Subcutaneous
start_date: '2024-08-10'
indication_for_use: Major depressive disorder
end_date: '2024-09-08'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-07'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed manager and advised fish.
- symptom_name: Maculopapular Rash
onset_date: '2024-09-07'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
- symptom_name: Angioedema
onset_date: '2024-09-07'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed benefit and advised religious.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Davis, Dennis and Hardy Medical Center
reporter_type: Nurse
notes: Level picture from base exist recently including. Congress as time task success
nation. Add upon be lot.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-221
Date of Submission: 2024-08-17
This report was submitted by a Other Healthcare Professional from Bell Ltd Medical Center concerning patient ANON-PX-9895. The subject is a 18-year-old male with a significant medical history including seasonal allergies, osteoarthritis, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Subcutaneous route at a dosage of 316mg, initiated on 2024-05-25 for Type 2 diabetes and discontinued on 2024-08-01.
On approximately 2024-07-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Diarrhea, Pruritus. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed somebody and advised soon. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed building and advised manager. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Second wall just whatever director rise base option. Must enter air serve thing business pressure fear. Growth situation study relate exactly. Push section camera place father bill what.</data>
|
report_id: ADR-2024-221
report_date: '2024-08-17'
patient_details:
patient_id: ANON-PX-9895
gender: Male
relevant_history:
- seasonal allergies
- osteoarthritis
- hypertension
age_at_reaction: 18
suspected_drugs:
- drug_name: Metformin
dosage: 316mg
route_of_administration: Subcutaneous
start_date: '2024-05-25'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-08-01'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-07-03'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-07-03'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed somebody and advised soon.
- symptom_name: Pruritus
onset_date: '2024-07-03'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed building and advised manager.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 6
reporting_facility: Bell Ltd Medical Center
reporter_type: Other Healthcare Professional
notes: Second wall just whatever director rise base option. Must enter air serve thing
business pressure fear. Growth situation study relate exactly. Push section camera
place father bill what.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-123
Date of Submission: 2024-09-16
This report was submitted by a Other Healthcare Professional from Flynn, Molina and Ortega Medical Center concerning patient ANON-PX-7493. The subject is a 36-year-old male with a significant medical history including asthma, chronic kidney disease, hypertension, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Intravenous route at a dosage of 227mg, initiated on 2024-08-04 for Bacterial infection and discontinued on 2024-09-13; Warfarin (Anticoagulant) administered via the Intramuscular route at a dosage of 208mg, initiated on 2024-08-04 for Thromboembolism prevention and discontinued on 2024-09-13.
On approximately 2024-08-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Vomiting, Somnolence, Dizziness. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed world and advised increase. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-123
report_date: '2024-09-16'
patient_details:
patient_id: ANON-PX-7493
gender: Male
relevant_history:
- asthma
- chronic kidney disease
- hypertension
- type 2 diabetes
age_at_reaction: 36
suspected_drugs:
- drug_name: Amoxicillin
dosage: 227mg
route_of_administration: Intravenous
start_date: '2024-08-04'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-09-13'
- drug_name: Warfarin
dosage: 208mg
route_of_administration: Intramuscular
start_date: '2024-08-04'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-09-13'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-08-12'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-08-12'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-08-12'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed world and advised increase.
- symptom_name: Dizziness
onset_date: '2024-08-12'
severity: Life-threatening
outcome: Fatal
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 6
reporting_facility: Flynn, Molina and Ortega Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-167
Date of Submission: 2024-11-05
This report was submitted by a Patient from Gordon-Short Medical Center concerning patient ANON-PX-8856. The subject is a 48-year-old male with a significant medical history including type 2 diabetes, coronary artery disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Subcutaneous route at a dosage of 450mg, initiated on 2024-09-07 for Major depressive disorder with the course ongoing; Atorvastatin administered via the Oral route at a dosage of 359mg, initiated on 2024-09-07 for Hypercholesterolemia with the course ongoing.
On approximately 2024-09-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Hepatotoxicity, Angioedema, Vomiting. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed condition and advised service. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed avoid and advised expert. The current patient status regarding this symptom is 'Unknown'. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-167
report_date: '2024-11-05'
patient_details:
patient_id: ANON-PX-8856
gender: Male
relevant_history:
- type 2 diabetes
- coronary artery disease
- migraines
age_at_reaction: 48
suspected_drugs:
- drug_name: Sertraline
dosage: 450mg
route_of_administration: Subcutaneous
start_date: '2024-09-07'
indication_for_use: Major depressive disorder
drug_class: SSRI
- drug_name: Atorvastatin
dosage: 359mg
route_of_administration: Oral
start_date: '2024-09-07'
indication_for_use: Hypercholesterolemia
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2024-09-17'
severity: Life-threatening
outcome: Recovered
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-09-17'
severity: Severe
outcome: Recovering
intervention_required: true
intervention_details: Prescribed condition and advised service.
- symptom_name: Angioedema
onset_date: '2024-09-17'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed avoid and advised expert.
- symptom_name: Vomiting
onset_date: '2024-09-17'
severity: Moderate
outcome: Unknown
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
reporting_facility: Gordon-Short Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-219
Date of Submission: 2025-04-15
This report was submitted by a Nurse from Martin PLC Medical Center concerning patient ANON-PX-2455. The subject is a 78-year-old female with a significant medical history including osteoarthritis, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Subcutaneous route at a dosage of 441mg, initiated on 2025-02-12 for Thromboembolism prevention with the course ongoing; Sertraline administered via the Intravenous route at a dosage of 392mg, initiated on 2025-02-12 for Major depressive disorder with the course ongoing.
On approximately 2025-04-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Pruritus, Stevens-Johnson syndrome. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed cover and advised suggest. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed method and advised range. The current patient status regarding this symptom is 'Recovering'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Step age article visit maintain opportunity option. Eight idea serious care into.</data>
|
report_id: ADR-2025-219
report_date: '2025-04-15'
patient_details:
patient_id: ANON-PX-2455
gender: Female
relevant_history:
- osteoarthritis
- seasonal allergies
age_at_reaction: 78
suspected_drugs:
- drug_name: Warfarin
dosage: 441mg
route_of_administration: Subcutaneous
start_date: '2025-02-12'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
- drug_name: Sertraline
dosage: 392mg
route_of_administration: Intravenous
start_date: '2025-02-12'
indication_for_use: Major depressive disorder
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2025-04-10'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed cover and advised suggest.
- symptom_name: Pruritus
onset_date: '2025-04-10'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed method and advised range.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-10'
severity: Mild
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 2
reporting_facility: Martin PLC Medical Center
reporter_type: Nurse
notes: Step age article visit maintain opportunity option. Eight idea serious care
into.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-656
Date of Submission: 2024-12-09
This report was submitted by a Patient from Morales, Schmitt and Williams Medical Center concerning patient ANON-PX-6741. The subject is a 57-year-old male with a significant medical history including type 2 diabetes, seasonal allergies, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intravenous route at a dosage of 378mg, initiated on 2024-10-08 for Hypercholesterolemia with the course ongoing; Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 239mg, initiated on 2024-10-08 for Hypertension with the course ongoing.
On approximately 2024-11-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Maculopapular Rash, Vomiting, Dizziness. The Hepatotoxicity was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed month and advised mother. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Door price late something impact also international.</data>
|
report_id: ADR-2024-656
report_date: '2024-12-09'
patient_details:
patient_id: ANON-PX-6741
gender: Male
relevant_history:
- type 2 diabetes
- seasonal allergies
- asthma
age_at_reaction: 57
suspected_drugs:
- drug_name: Atorvastatin
dosage: 378mg
route_of_administration: Intravenous
start_date: '2024-10-08'
indication_for_use: Hypercholesterolemia
- drug_name: Lisinopril
dosage: 239mg
route_of_administration: Oral
start_date: '2024-10-08'
indication_for_use: Hypertension
drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-11-07'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed month and advised mother.
- symptom_name: Maculopapular Rash
onset_date: '2024-11-07'
severity: Moderate
outcome: Recovered
intervention_required: true
- symptom_name: Vomiting
onset_date: '2024-11-07'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-11-07'
severity: Severe
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 8
reporting_facility: Morales, Schmitt and Williams Medical Center
reporter_type: Patient
notes: Door price late something impact also international.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-529
Date of Submission: 2025-04-17
This report was submitted by a Patient from Jackson Inc Medical Center concerning patient ANON-PX-5979. The subject is an adult male with a significant medical history including anxiety, hypertension, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin administered via the Intramuscular route at a dosage of 96mg, initiated on 2025-03-19 for Thromboembolism prevention and discontinued on 2025-04-05.
On approximately 2025-03-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Hepatotoxicity, Anaphylaxis, Angioedema. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed recognize and advised writer. The current patient status regarding this symptom is 'Not Recovered'. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed space and advised yet. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Boy include out room. Mother century life view sell which. International step son security.</data>
|
report_id: ADR-2025-529
report_date: '2025-04-17'
patient_details:
patient_id: ANON-PX-5979
gender: Male
relevant_history:
- anxiety
- hypertension
- chronic kidney disease
suspected_drugs:
- drug_name: Warfarin
dosage: 96mg
route_of_administration: Intramuscular
start_date: '2025-03-19'
indication_for_use: Thromboembolism prevention
end_date: '2025-04-05'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-03-25'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed recognize and advised writer.
- symptom_name: Hepatotoxicity
onset_date: '2025-03-25'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed space and advised yet.
- symptom_name: Anaphylaxis
onset_date: '2025-03-25'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Angioedema
onset_date: '2025-03-25'
severity: Severe
outcome: Unknown
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 6
reporting_facility: Jackson Inc Medical Center
reporter_type: Patient
notes: Boy include out room. Mother century life view sell which. International step
son security.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-296
Date of Submission: 2024-12-19
This report was submitted by a Physician from Shelton, Woods and Kim Medical Center concerning patient ANON-PX-4455. The subject is a 77-year-old male with a significant medical history including osteoarthritis, migraines, asthma, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline administered via the Topical route at a dosage of 168mg, initiated on 2024-09-26 for Major depressive disorder and discontinued on 2024-12-15; Amoxicillin (Penicillin antibiotic) administered via the Intramuscular route at a dosage of 237mg, initiated on 2024-09-26 for Bacterial infection and discontinued on 2024-12-15.
On approximately 2024-12-15, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Headache, Maculopapular Rash, Diarrhea, Vomiting, Stevens-Johnson syndrome. The Headache was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Director their until while call. Choose hard bar may lead improve quickly. Realize record trade vote rise.</data>
|
report_id: ADR-2024-296
report_date: '2024-12-19'
patient_details:
patient_id: ANON-PX-4455
gender: Male
relevant_history:
- osteoarthritis
- migraines
- asthma
- anxiety
age_at_reaction: 77
suspected_drugs:
- drug_name: Sertraline
dosage: 168mg
route_of_administration: Topical
start_date: '2024-09-26'
indication_for_use: Major depressive disorder
end_date: '2024-12-15'
- drug_name: Amoxicillin
dosage: 237mg
route_of_administration: Intramuscular
start_date: '2024-09-26'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-12-15'
adverse_reactions:
- symptom_name: Headache
onset_date: '2024-12-15'
severity: Life-threatening
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-15'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-12-15'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-12-15'
severity: Severe
outcome: Not Recovered
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-12-15'
severity: Moderate
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 9
reporting_facility: Shelton, Woods and Kim Medical Center
reporter_type: Physician
notes: Director their until while call. Choose hard bar may lead improve quickly.
Realize record trade vote rise.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-552
Date of Submission: 2025-05-06
This report was submitted by a Physician from Adams-Parks Medical Center concerning patient ANON-PX-1845. The subject is a 52-year-old female with a significant medical history including anxiety, seasonal allergies, migraines, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Subcutaneous route at a dosage of 211mg, initiated on 2025-02-07 for Bacterial infection with the course ongoing; Atorvastatin (Statin) administered via the Topical route at a dosage of 195mg, initiated on 2025-02-07 for Hypercholesterolemia with the course ongoing.
On approximately 2025-04-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Anaphylaxis. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed past and advised cover. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed eye and advised million. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Authority light civil discuss democratic. Station million color blood watch.</data>
|
report_id: ADR-2025-552
report_date: '2025-05-06'
patient_details:
patient_id: ANON-PX-1845
gender: Female
relevant_history:
- anxiety
- seasonal allergies
- migraines
- type 2 diabetes
age_at_reaction: 52
suspected_drugs:
- drug_name: Amoxicillin
dosage: 211mg
route_of_administration: Subcutaneous
start_date: '2025-02-07'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
- drug_name: Atorvastatin
dosage: 195mg
route_of_administration: Topical
start_date: '2025-02-07'
indication_for_use: Hypercholesterolemia
drug_class: Statin
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-04-11'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed past and advised cover.
- symptom_name: Anaphylaxis
onset_date: '2025-04-11'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed eye and advised million.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Adams-Parks Medical Center
reporter_type: Physician
notes: Authority light civil discuss democratic. Station million color blood watch.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-934
Date of Submission: 2025-02-20
This report was submitted by a Other Healthcare Professional from Conley, Rodriguez and Harris Medical Center concerning patient ANON-PX-5394. The subject is an adult other with a significant medical history including hypertension, anxiety, asthma, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Gabapentin administered via the Intravenous route at a dosage of 155mg, initiated on 2024-11-25 for Neuropathic pain and discontinued on 2025-02-19; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 313mg, initiated on 2024-11-25 for Thromboembolism prevention and discontinued on 2025-02-19.
On approximately 2025-02-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Vomiting, Headache. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed hundred and advised western. The current patient status regarding this symptom is 'Recovered'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed economy and advised between. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 4 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-934
report_date: '2025-02-20'
patient_details:
patient_id: ANON-PX-5394
gender: Other
relevant_history:
- hypertension
- anxiety
- asthma
- osteoarthritis
suspected_drugs:
- drug_name: Gabapentin
dosage: 155mg
route_of_administration: Intravenous
start_date: '2024-11-25'
indication_for_use: Neuropathic pain
end_date: '2025-02-19'
- drug_name: Warfarin
dosage: 313mg
route_of_administration: Intravenous
start_date: '2024-11-25'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-02-19'
adverse_reactions:
- symptom_name: Angioedema
onset_date: '2025-02-03'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed hundred and advised western.
- symptom_name: Vomiting
onset_date: '2025-02-03'
severity: Life-threatening
outcome: Unknown
intervention_required: true
- symptom_name: Headache
onset_date: '2025-02-03'
severity: Life-threatening
outcome: Unknown
intervention_required: true
intervention_details: Prescribed economy and advised between.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 4
reporting_facility: Conley, Rodriguez and Harris Medical Center
reporter_type: Other Healthcare Professional
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-644
Date of Submission: 2024-12-12
This report was submitted by a Other Healthcare Professional from Brennan-Medina Medical Center concerning patient ANON-PX-5324. The subject is a 62-year-old other with a significant medical history including hypertension, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Oral route at a dosage of 176mg, initiated on 2024-10-22 for Bacterial infection and discontinued on 2024-11-28; Atorvastatin (Statin) administered via the Subcutaneous route at a dosage of 14mg, initiated on 2024-10-22 for Hypercholesterolemia and discontinued on 2024-11-28.
On approximately 2024-10-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Pruritus. The Vomiting was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed do and advised again. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Individual game edge involve. Account draw pay southern attention grow.</data>
|
report_id: ADR-2024-644
report_date: '2024-12-12'
patient_details:
patient_id: ANON-PX-5324
gender: Other
relevant_history:
- hypertension
- asthma
age_at_reaction: 62
suspected_drugs:
- drug_name: Amoxicillin
dosage: 176mg
route_of_administration: Oral
start_date: '2024-10-22'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-11-28'
- drug_name: Atorvastatin
dosage: 14mg
route_of_administration: Subcutaneous
start_date: '2024-10-22'
indication_for_use: Hypercholesterolemia
drug_class: Statin
end_date: '2024-11-28'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-10-29'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-10-29'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed do and advised again.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 1
reporting_facility: Brennan-Medina Medical Center
reporter_type: Other Healthcare Professional
notes: Individual game edge involve. Account draw pay southern attention grow.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-661
Date of Submission: 2024-08-18
This report was submitted by a Other Healthcare Professional from Sawyer and Sons Medical Center concerning patient ANON-PX-8462. The subject is a 27-year-old male with a significant medical history including chronic kidney disease, migraines, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Topical route at a dosage of 166mg, initiated on 2024-06-18 for Bacterial infection and discontinued on 2024-07-26; Metformin (Biguanide) administered via the Subcutaneous route at a dosage of 441mg, initiated on 2024-06-18 for Type 2 diabetes and discontinued on 2024-07-26.
On approximately 2024-07-25, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Maculopapular Rash, Headache, Somnolence, Diarrhea. The Dizziness was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed no and advised range. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Only effort newspaper worry measure there. There realize but usually send program performance.</data>
|
report_id: ADR-2024-661
report_date: '2024-08-18'
patient_details:
patient_id: ANON-PX-8462
gender: Male
relevant_history:
- chronic kidney disease
- migraines
- atrial fibrillation
age_at_reaction: 27
suspected_drugs:
- drug_name: Amoxicillin
dosage: 166mg
route_of_administration: Topical
start_date: '2024-06-18'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2024-07-26'
- drug_name: Metformin
dosage: 441mg
route_of_administration: Subcutaneous
start_date: '2024-06-18'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-07-26'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-07-25'
severity: Mild
outcome: Recovered
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-07-25'
severity: Mild
outcome: Not Recovered
intervention_required: true
- symptom_name: Headache
onset_date: '2024-07-25'
severity: Moderate
outcome: Unknown
intervention_required: true
- symptom_name: Somnolence
onset_date: '2024-07-25'
severity: Mild
outcome: Recovering
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2024-07-25'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed no and advised range.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 1
reporting_facility: Sawyer and Sons Medical Center
reporter_type: Other Healthcare Professional
notes: Only effort newspaper worry measure there. There realize but usually send program
performance.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-384
Date of Submission: 2025-01-28
This report was submitted by a Physician from Simmons-Mitchell Medical Center concerning patient ANON-PX-5226. The subject is a 67-year-old male with a significant medical history including chronic kidney disease, hypertension, atrial fibrillation, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 483mg, initiated on 2024-11-10 for Pain and inflammation with the course ongoing; Amoxicillin (Penicillin antibiotic) administered via the Topical route at a dosage of 492mg, initiated on 2024-11-10 for Bacterial infection with the course ongoing.
On approximately 2024-12-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Maculopapular Rash, Anaphylaxis, Angioedema. The Somnolence was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed resource and advised service. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 8 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Relationship if them ok team visit begin score. Move somebody anything receive soon catch share. Provide discover account play field pattern.</data>
|
report_id: ADR-2025-384
report_date: '2025-01-28'
patient_details:
patient_id: ANON-PX-5226
gender: Male
relevant_history:
- chronic kidney disease
- hypertension
- atrial fibrillation
- coronary artery disease
age_at_reaction: 67
suspected_drugs:
- drug_name: Ibuprofen
dosage: 483mg
route_of_administration: Intramuscular
start_date: '2024-11-10'
indication_for_use: Pain and inflammation
drug_class: NSAID
- drug_name: Amoxicillin
dosage: 492mg
route_of_administration: Topical
start_date: '2024-11-10'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2024-12-04'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed resource and advised service.
- symptom_name: Maculopapular Rash
onset_date: '2024-12-04'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2024-12-04'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-12-04'
severity: Severe
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
naranjo_score: 8
reporting_facility: Simmons-Mitchell Medical Center
reporter_type: Physician
notes: Relationship if them ok team visit begin score. Move somebody anything receive
soon catch share. Provide discover account play field pattern.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-825
Date of Submission: 2024-10-30
This report was submitted by a Physician from Johnson-Hooper Medical Center concerning patient ANON-PX-8247. The subject is a 76-year-old male with a significant medical history including chronic kidney disease, hypertension, atrial fibrillation, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 310mg, initiated on 2024-08-31 for Hypothyroidism and discontinued on 2024-09-05.
On approximately 2024-09-05, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Headache, Pruritus. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed too and advised letter. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed scientist and advised age. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-825
report_date: '2024-10-30'
patient_details:
patient_id: ANON-PX-8247
gender: Male
relevant_history:
- chronic kidney disease
- hypertension
- atrial fibrillation
- coronary artery disease
age_at_reaction: 76
suspected_drugs:
- drug_name: Levothyroxine
dosage: 310mg
route_of_administration: Oral
start_date: '2024-08-31'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-09-05'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-09-05'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed too and advised letter.
- symptom_name: Headache
onset_date: '2024-09-05'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Pruritus
onset_date: '2024-09-05'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed scientist and advised age.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 5
reporting_facility: Johnson-Hooper Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-193
Date of Submission: 2025-06-16
This report was submitted by a Patient from Acosta and Sons Medical Center concerning patient ANON-PX-7549. The subject is an adult male with a significant medical history including osteoarthritis, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril administered via the Intramuscular route at a dosage of 379mg, initiated on 2025-05-26 for Hypertension and discontinued on 2025-06-13; Metformin administered via the Intramuscular route at a dosage of 439mg, initiated on 2025-05-26 for Type 2 diabetes and discontinued on 2025-06-13.
On approximately 2025-06-12, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Pruritus. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Pruritus was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed must and advised act. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-193
report_date: '2025-06-16'
patient_details:
patient_id: ANON-PX-7549
gender: Male
relevant_history:
- osteoarthritis
- migraines
suspected_drugs:
- drug_name: Lisinopril
dosage: 379mg
route_of_administration: Intramuscular
start_date: '2025-05-26'
indication_for_use: Hypertension
end_date: '2025-06-13'
- drug_name: Metformin
dosage: 439mg
route_of_administration: Intramuscular
start_date: '2025-05-26'
indication_for_use: Type 2 diabetes
end_date: '2025-06-13'
adverse_reactions:
- symptom_name: Anaphylaxis
onset_date: '2025-06-12'
severity: Moderate
outcome: Not Recovered
intervention_required: true
- symptom_name: Pruritus
onset_date: '2025-06-12'
severity: Severe
outcome: Recovered
intervention_required: true
intervention_details: Prescribed must and advised act.
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Not applicable
naranjo_score: 1
reporting_facility: Acosta and Sons Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-514
Date of Submission: 2025-06-30
This report was submitted by a Pharmacist from Hanson, Lewis and Lewis Medical Center concerning patient ANON-PX-5025. The subject is an adult other with a significant medical history including seasonal allergies, osteoarthritis, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Amoxicillin (Penicillin antibiotic) administered via the Subcutaneous route at a dosage of 348mg, initiated on 2025-05-02 for Bacterial infection and discontinued on 2025-06-23.
On approximately 2025-06-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Anaphylaxis. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed vote and advised Mr. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Run whom personal box fire own. Push energy matter much just.</data>
|
report_id: ADR-2025-514
report_date: '2025-06-30'
patient_details:
patient_id: ANON-PX-5025
gender: Other
relevant_history:
- seasonal allergies
- osteoarthritis
- chronic kidney disease
suspected_drugs:
- drug_name: Amoxicillin
dosage: 348mg
route_of_administration: Subcutaneous
start_date: '2025-05-02'
indication_for_use: Bacterial infection
drug_class: Penicillin antibiotic
end_date: '2025-06-23'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2025-06-22'
severity: Severe
outcome: Recovered
intervention_required: true
- symptom_name: Anaphylaxis
onset_date: '2025-06-22'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed vote and advised Mr.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Hanson, Lewis and Lewis Medical Center
reporter_type: Pharmacist
notes: Run whom personal box fire own. Push energy matter much just.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-697
Date of Submission: 2024-11-02
This report was submitted by a Patient from Bradley-Wells Medical Center concerning patient ANON-PX-8536. The subject is an adult male with a significant medical history including seasonal allergies, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin administered via the Topical route at a dosage of 364mg, initiated on 2024-10-25 for Thromboembolism prevention and discontinued on 2024-10-31.
On approximately 2024-10-29, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Diarrhea. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed PM and advised east. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-697
report_date: '2024-11-02'
patient_details:
patient_id: ANON-PX-8536
gender: Male
relevant_history:
- seasonal allergies
- hypertension
suspected_drugs:
- drug_name: Warfarin
dosage: 364mg
route_of_administration: Topical
start_date: '2024-10-25'
indication_for_use: Thromboembolism prevention
end_date: '2024-10-31'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-10-29'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2024-10-29'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed PM and advised east.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 7
reporting_facility: Bradley-Wells Medical Center
reporter_type: Patient
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-330
Date of Submission: 2024-10-06
This report was submitted by a Pharmacist from Frank-Anderson Medical Center concerning patient ANON-PX-3486. The subject is an adult male with a significant medical history including hypertension, seasonal allergies, osteoarthritis, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Metformin (Biguanide) administered via the Topical route at a dosage of 69mg, initiated on 2024-07-11 for Type 2 diabetes and discontinued on 2024-09-11; Atorvastatin administered via the Oral route at a dosage of 131mg, initiated on 2024-07-11 for Hypercholesterolemia and discontinued on 2024-09-11.
On approximately 2024-08-22, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Hepatotoxicity, Stevens-Johnson syndrome. The Vomiting was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed argue and advised girl. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-330
report_date: '2024-10-06'
patient_details:
patient_id: ANON-PX-3486
gender: Male
relevant_history:
- hypertension
- seasonal allergies
- osteoarthritis
- coronary artery disease
suspected_drugs:
- drug_name: Metformin
dosage: 69mg
route_of_administration: Topical
start_date: '2024-07-11'
indication_for_use: Type 2 diabetes
drug_class: Biguanide
end_date: '2024-09-11'
- drug_name: Atorvastatin
dosage: 131mg
route_of_administration: Oral
start_date: '2024-07-11'
indication_for_use: Hypercholesterolemia
end_date: '2024-09-11'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-08-22'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-08-22'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed argue and advised girl.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-08-22'
severity: Moderate
outcome: Unknown
intervention_required: true
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 10
reporting_facility: Frank-Anderson Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-470
Date of Submission: 2024-12-28
This report was submitted by a Other Healthcare Professional from Campbell, Cunningham and French Medical Center concerning patient ANON-PX-1887. The subject is a 85-year-old male with a significant medical history including chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 24mg, initiated on 2024-11-10 for Thromboembolism prevention and discontinued on 2024-12-23; Gabapentin (Anticonvulsant) administered via the Intravenous route at a dosage of 476mg, initiated on 2024-11-10 for Neuropathic pain and discontinued on 2024-12-23.
On approximately 2024-12-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Maculopapular Rash, Hepatotoxicity, Vomiting, Anaphylaxis. The Dizziness was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed necessary and advised through. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Of large often window way away. Own nature west already.</data>
|
report_id: ADR-2024-470
report_date: '2024-12-28'
patient_details:
patient_id: ANON-PX-1887
gender: Male
relevant_history:
- chronic kidney disease
- anxiety
age_at_reaction: 85
suspected_drugs:
- drug_name: Warfarin
dosage: 24mg
route_of_administration: Intravenous
start_date: '2024-11-10'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-12-23'
- drug_name: Gabapentin
dosage: 476mg
route_of_administration: Intravenous
start_date: '2024-11-10'
indication_for_use: Neuropathic pain
drug_class: Anticonvulsant
end_date: '2024-12-23'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-12-13'
severity: Severe
outcome: Unknown
intervention_required: false
- symptom_name: Maculopapular Rash
onset_date: '2024-12-13'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-12-13'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Vomiting
onset_date: '2024-12-13'
severity: Life-threatening
outcome: Recovering
intervention_required: true
intervention_details: Prescribed necessary and advised through.
- symptom_name: Anaphylaxis
onset_date: '2024-12-13'
severity: Moderate
outcome: Recovered
intervention_required: true
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Campbell, Cunningham and French Medical Center
reporter_type: Other Healthcare Professional
notes: Of large often window way away. Own nature west already.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-434
Date of Submission: 2025-07-09
This report was submitted by a Nurse from Castillo and Sons Medical Center concerning patient ANON-PX-8962. The subject is a 31-year-old female with a significant medical history including osteoarthritis, atrial fibrillation, seasonal allergies, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 343mg, initiated on 2025-06-11 for Gastroesophageal reflux disease with the course ongoing; Lisinopril administered via the Oral route at a dosage of 191mg, initiated on 2025-06-11 for Hypertension with the course ongoing.
On approximately 2025-07-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Dizziness, Nausea. The Hepatotoxicity was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed better and advised measure. The current patient status regarding this symptom is 'Recovering'. The Dizziness was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed team and advised him. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Certainly when third. Certain season worry them kind century official.</data>
|
report_id: ADR-2025-434
report_date: '2025-07-09'
patient_details:
patient_id: ANON-PX-8962
gender: Female
relevant_history:
- osteoarthritis
- atrial fibrillation
- seasonal allergies
- anxiety
age_at_reaction: 31
suspected_drugs:
- drug_name: Omeprazole
dosage: 343mg
route_of_administration: Intramuscular
start_date: '2025-06-11'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
- drug_name: Lisinopril
dosage: 191mg
route_of_administration: Oral
start_date: '2025-06-11'
indication_for_use: Hypertension
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-07-01'
severity: Moderate
outcome: Recovering
intervention_required: true
intervention_details: Prescribed better and advised measure.
- symptom_name: Dizziness
onset_date: '2025-07-01'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-07-01'
severity: Life-threatening
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed team and advised him.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
reporting_facility: Castillo and Sons Medical Center
reporter_type: Nurse
notes: Certainly when third. Certain season worry them kind century official.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-498
Date of Submission: 2025-03-13
This report was submitted by a Nurse from Allen, Johnson and Sweeney Medical Center concerning patient ANON-PX-1851. The subject is a 56-year-old female with a significant medical history including osteoarthritis, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intramuscular route at a dosage of 24mg, initiated on 2024-12-31 for Hypercholesterolemia with the course ongoing; Warfarin (Anticoagulant) administered via the Topical route at a dosage of 472mg, initiated on 2024-12-31 for Thromboembolism prevention with the course ongoing.
On approximately 2025-03-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Vomiting, Diarrhea. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed and and advised age. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-498
report_date: '2025-03-13'
patient_details:
patient_id: ANON-PX-1851
gender: Female
relevant_history:
- osteoarthritis
- chronic kidney disease
age_at_reaction: 56
suspected_drugs:
- drug_name: Atorvastatin
dosage: 24mg
route_of_administration: Intramuscular
start_date: '2024-12-31'
indication_for_use: Hypercholesterolemia
- drug_name: Warfarin
dosage: 472mg
route_of_administration: Topical
start_date: '2024-12-31'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-03-01'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Vomiting
onset_date: '2025-03-01'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed and and advised age.
- symptom_name: Diarrhea
onset_date: '2025-03-01'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 3
reporting_facility: Allen, Johnson and Sweeney Medical Center
reporter_type: Nurse
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-439
Date of Submission: 2025-04-25
This report was submitted by a Nurse from Reed-Koch Medical Center concerning patient ANON-PX-4794. The subject is a 52-year-old male with a significant medical history including osteoarthritis, chronic kidney disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin administered via the Intravenous route at a dosage of 115mg, initiated on 2025-02-27 for Hypercholesterolemia with the course ongoing.
On approximately 2025-04-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Nausea. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Mouth available feel public member only. Ago shoulder hospital single. Tree prevent enter practice development.</data>
|
report_id: ADR-2025-439
report_date: '2025-04-25'
patient_details:
patient_id: ANON-PX-4794
gender: Male
relevant_history:
- osteoarthritis
- chronic kidney disease
- seasonal allergies
age_at_reaction: 52
suspected_drugs:
- drug_name: Atorvastatin
dosage: 115mg
route_of_administration: Intravenous
start_date: '2025-02-27'
indication_for_use: Hypercholesterolemia
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-04-08'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-04-08'
severity: Life-threatening
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 5
reporting_facility: Reed-Koch Medical Center
reporter_type: Nurse
notes: Mouth available feel public member only. Ago shoulder hospital single. Tree
prevent enter practice development.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-336
Date of Submission: 2025-06-13
This report was submitted by a Physician from Smith PLC Medical Center concerning patient ANON-PX-8919. The subject is a 84-year-old other with a significant medical history including asthma, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Oral route at a dosage of 219mg, initiated on 2025-05-20 for Thromboembolism prevention with the course ongoing.
On approximately 2025-05-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Diarrhea, Somnolence. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed traditional and advised against. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Somnolence was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-336
report_date: '2025-06-13'
patient_details:
patient_id: ANON-PX-8919
gender: Other
relevant_history:
- asthma
- type 2 diabetes
age_at_reaction: 84
suspected_drugs:
- drug_name: Warfarin
dosage: 219mg
route_of_administration: Oral
start_date: '2025-05-20'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-05-23'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed traditional and advised against.
- symptom_name: Diarrhea
onset_date: '2025-05-23'
severity: Severe
outcome: Recovered
intervention_required: true
- symptom_name: Somnolence
onset_date: '2025-05-23'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Smith PLC Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-309
Date of Submission: 2024-12-26
This report was submitted by a Physician from Hopkins PLC Medical Center concerning patient ANON-PX-3418. The subject is a 70-year-old other with a significant medical history including hypertension, migraines, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Topical route at a dosage of 366mg, initiated on 2024-11-26 for Hypothyroidism and discontinued on 2024-12-20.
On approximately 2024-12-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Somnolence, Nausea, Dizziness, Angioedema, Diarrhea. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Dizziness was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed present and advised newspaper. The current patient status regarding this symptom is 'Not Recovered'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Diarrhea was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2024-309
report_date: '2024-12-26'
patient_details:
patient_id: ANON-PX-3418
gender: Other
relevant_history:
- hypertension
- migraines
- coronary artery disease
age_at_reaction: 70
suspected_drugs:
- drug_name: Levothyroxine
dosage: 366mg
route_of_administration: Topical
start_date: '2024-11-26'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-12-20'
adverse_reactions:
- symptom_name: Somnolence
onset_date: '2024-12-01'
severity: Moderate
outcome: Fatal
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-12-01'
severity: Moderate
outcome: Unknown
intervention_required: false
- symptom_name: Dizziness
onset_date: '2024-12-01'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed present and advised newspaper.
- symptom_name: Angioedema
onset_date: '2024-12-01'
severity: Mild
outcome: Recovering
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-12-01'
severity: Mild
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 1
reporting_facility: Hopkins PLC Medical Center
reporter_type: Physician
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-529
Date of Submission: 2025-03-26
This report was submitted by a Pharmacist from Thompson-Clark Medical Center concerning patient ANON-PX-7039. The subject is an adult female with a significant medical history including migraines, chronic kidney disease, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Intramuscular route at a dosage of 488mg, initiated on 2025-03-16 for Pain and inflammation with the course ongoing.
On approximately 2025-03-17, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Stevens-Johnson syndrome. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed only and advised walk. The current patient status regarding this symptom is 'Recovered'. The Stevens-Johnson syndrome was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
</data>
|
report_id: ADR-2025-529
report_date: '2025-03-26'
patient_details:
patient_id: ANON-PX-7039
gender: Female
relevant_history:
- migraines
- chronic kidney disease
- anxiety
suspected_drugs:
- drug_name: Ibuprofen
dosage: 488mg
route_of_administration: Intramuscular
start_date: '2025-03-16'
indication_for_use: Pain and inflammation
drug_class: NSAID
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-03-17'
severity: Mild
outcome: Recovered
intervention_required: true
intervention_details: Prescribed only and advised walk.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-03-17'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 5
reporting_facility: Thompson-Clark Medical Center
reporter_type: Pharmacist
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-348
Date of Submission: 2025-03-10
This report was submitted by a Nurse from Burns-Glenn Medical Center concerning patient ANON-PX-2115. The subject is a 66-year-old female with a significant medical history including chronic kidney disease, seasonal allergies, anxiety, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Oral route at a dosage of 267mg, initiated on 2025-01-05 for Thromboembolism prevention with the course ongoing.
On approximately 2025-01-31, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Nausea, Diarrhea. The Vomiting was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Diarrhea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed change and advised set. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Win serious but size short. Coach have remain story west. Clearly PM never account choice factor skin.</data>
|
report_id: ADR-2025-348
report_date: '2025-03-10'
patient_details:
patient_id: ANON-PX-2115
gender: Female
relevant_history:
- chronic kidney disease
- seasonal allergies
- anxiety
- asthma
age_at_reaction: 66
suspected_drugs:
- drug_name: Warfarin
dosage: 267mg
route_of_administration: Oral
start_date: '2025-01-05'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-01-31'
severity: Mild
outcome: Not Recovered
intervention_required: false
- symptom_name: Nausea
onset_date: '2025-01-31'
severity: Life-threatening
outcome: Recovered
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2025-01-31'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed change and advised set.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 9
reporting_facility: Burns-Glenn Medical Center
reporter_type: Nurse
notes: Win serious but size short. Coach have remain story west. Clearly PM never
account choice factor skin.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-567
Date of Submission: 2025-01-19
This report was submitted by a Patient from Michael-Davis Medical Center concerning patient ANON-PX-1090. The subject is a 85-year-old other with a significant medical history including type 2 diabetes, osteoarthritis, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Intramuscular route at a dosage of 268mg, initiated on 2024-12-04 for Gastroesophageal reflux disease and discontinued on 2025-01-17; Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 495mg, initiated on 2024-12-04 for Hypertension and discontinued on 2025-01-17.
On approximately 2025-01-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Stevens-Johnson syndrome, Maculopapular Rash. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed high and advised type. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: He politics life however huge message. Since seven ahead.</data>
|
report_id: ADR-2025-567
report_date: '2025-01-19'
patient_details:
patient_id: ANON-PX-1090
gender: Other
relevant_history:
- type 2 diabetes
- osteoarthritis
- asthma
age_at_reaction: 85
suspected_drugs:
- drug_name: Omeprazole
dosage: 268mg
route_of_administration: Intramuscular
start_date: '2024-12-04'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-01-17'
- drug_name: Lisinopril
dosage: 495mg
route_of_administration: Oral
start_date: '2024-12-04'
indication_for_use: Hypertension
drug_class: ACE inhibitor
end_date: '2025-01-17'
adverse_reactions:
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-01-01'
severity: Mild
outcome: Recovered
intervention_required: true
- symptom_name: Maculopapular Rash
onset_date: '2025-01-01'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed high and advised type.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 10
reporting_facility: Michael-Davis Medical Center
reporter_type: Patient
notes: He politics life however huge message. Since seven ahead.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-637
Date of Submission: 2024-11-27
This report was submitted by a Patient from Walker, Smith and Hawkins Medical Center concerning patient ANON-PX-3000. The subject is a 73-year-old female with a significant medical history including coronary artery disease, asthma, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Oral route at a dosage of 484mg, initiated on 2024-09-06 for Hypertension with the course ongoing.
On approximately 2024-11-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Diarrhea, Somnolence, Angioedema, Headache. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed enough and advised yes. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Angioedema was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed realize and advised church. The current patient status regarding this symptom is 'Not Recovered'. The Headache was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed thousand and advised with. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Nearly recently you energy look. Strong something short top evening yet once.</data>
|
report_id: ADR-2024-637
report_date: '2024-11-27'
patient_details:
patient_id: ANON-PX-3000
gender: Female
relevant_history:
- coronary artery disease
- asthma
- hypertension
age_at_reaction: 73
suspected_drugs:
- drug_name: Lisinopril
dosage: 484mg
route_of_administration: Oral
start_date: '2024-09-06'
indication_for_use: Hypertension
drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-11-07'
severity: Mild
outcome: Not Recovered
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2024-11-07'
severity: Life-threatening
outcome: Fatal
intervention_required: true
intervention_details: Prescribed enough and advised yes.
- symptom_name: Somnolence
onset_date: '2024-11-07'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-11-07'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed realize and advised church.
- symptom_name: Headache
onset_date: '2024-11-07'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed thousand and advised with.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Walker, Smith and Hawkins Medical Center
reporter_type: Patient
notes: Nearly recently you energy look. Strong something short top evening yet once.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-365
Date of Submission: 2024-09-10
This report was submitted by a Pharmacist from Chavez LLC Medical Center concerning patient ANON-PX-5066. The subject is an adult other with a significant medical history including chronic kidney disease, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Oral route at a dosage of 483mg, initiated on 2024-07-03 for Hypothyroidism and discontinued on 2024-07-31.
On approximately 2024-07-08, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Dizziness, Nausea, Somnolence, Hepatotoxicity. The Maculopapular Rash was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed take and advised thank. The current patient status regarding this symptom is 'Fatal'. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Nausea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Somnolence was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Later turn house talk. May consider wall offer. Spend describe miss.</data>
|
report_id: ADR-2024-365
report_date: '2024-09-10'
patient_details:
patient_id: ANON-PX-5066
gender: Other
relevant_history:
- chronic kidney disease
- atrial fibrillation
suspected_drugs:
- drug_name: Levothyroxine
dosage: 483mg
route_of_administration: Oral
start_date: '2024-07-03'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
end_date: '2024-07-31'
adverse_reactions:
- symptom_name: Maculopapular Rash
onset_date: '2024-07-08'
severity: Severe
outcome: Fatal
intervention_required: true
intervention_details: Prescribed take and advised thank.
- symptom_name: Dizziness
onset_date: '2024-07-08'
severity: Mild
outcome: Fatal
intervention_required: true
- symptom_name: Nausea
onset_date: '2024-07-08'
severity: Severe
outcome: Recovering
intervention_required: false
- symptom_name: Somnolence
onset_date: '2024-07-08'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Hepatotoxicity
onset_date: '2024-07-08'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 3
reporting_facility: Chavez LLC Medical Center
reporter_type: Pharmacist
notes: Later turn house talk. May consider wall offer. Spend describe miss.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-405
Date of Submission: 2025-03-10
This report was submitted by a Physician from Davis, Bell and Rivera Medical Center concerning patient ANON-PX-6659. The subject is a 48-year-old other with a significant medical history including asthma, chronic kidney disease, type 2 diabetes, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Intramuscular route at a dosage of 419mg, initiated on 2025-01-17 for Hypertension with the course ongoing; Amoxicillin administered via the Oral route at a dosage of 193mg, initiated on 2025-01-17 for Bacterial infection with the course ongoing.
On approximately 2025-03-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Stevens-Johnson syndrome, Anaphylaxis. The Dizziness was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed fast and advised discuss. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 3 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Including bed goal dream. Structure century return fear.</data>
|
report_id: ADR-2025-405
report_date: '2025-03-10'
patient_details:
patient_id: ANON-PX-6659
gender: Other
relevant_history:
- asthma
- chronic kidney disease
- type 2 diabetes
- atrial fibrillation
age_at_reaction: 48
suspected_drugs:
- drug_name: Lisinopril
dosage: 419mg
route_of_administration: Intramuscular
start_date: '2025-01-17'
indication_for_use: Hypertension
drug_class: ACE inhibitor
- drug_name: Amoxicillin
dosage: 193mg
route_of_administration: Oral
start_date: '2025-01-17'
indication_for_use: Bacterial infection
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2025-03-04'
severity: Life-threatening
outcome: Fatal
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-03-04'
severity: Moderate
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed fast and advised discuss.
- symptom_name: Anaphylaxis
onset_date: '2025-03-04'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Possible
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 3
reporting_facility: Davis, Bell and Rivera Medical Center
reporter_type: Physician
notes: Including bed goal dream. Structure century return fear.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-876
Date of Submission: 2025-02-10
This report was submitted by a Patient from Moss Inc Medical Center concerning patient ANON-PX-3359. The subject is an adult female with a significant medical history including asthma, coronary artery disease, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Topical route at a dosage of 83mg, initiated on 2025-01-30 for Pain and inflammation and discontinued on 2025-02-07; Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 481mg, initiated on 2025-01-30 for Thromboembolism prevention and discontinued on 2025-02-07.
On approximately 2025-02-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Stevens-Johnson syndrome, Diarrhea. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Severe in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Fatal'. The Diarrhea was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Woman instead top prove material history.</data>
|
report_id: ADR-2025-876
report_date: '2025-02-10'
patient_details:
patient_id: ANON-PX-3359
gender: Female
relevant_history:
- asthma
- coronary artery disease
- seasonal allergies
suspected_drugs:
- drug_name: Ibuprofen
dosage: 83mg
route_of_administration: Topical
start_date: '2025-01-30'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2025-02-07'
- drug_name: Warfarin
dosage: 481mg
route_of_administration: Intravenous
start_date: '2025-01-30'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2025-02-07'
adverse_reactions:
- symptom_name: Pruritus
onset_date: '2025-02-07'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Stevens-Johnson syndrome
onset_date: '2025-02-07'
severity: Severe
outcome: Fatal
intervention_required: true
- symptom_name: Diarrhea
onset_date: '2025-02-07'
severity: Severe
outcome: Fatal
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Negative dechallenge
reporting_facility: Moss Inc Medical Center
reporter_type: Patient
notes: Woman instead top prove material history.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-597
Date of Submission: 2024-12-29
This report was submitted by a Pharmacist from Bailey PLC Medical Center concerning patient ANON-PX-5981. The subject is an adult male with a significant medical history including migraines, seasonal allergies, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Oral route at a dosage of 326mg, initiated on 2024-11-16 for Thromboembolism prevention and discontinued on 2024-12-12.
On approximately 2024-12-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Stevens-Johnson syndrome. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed another and advised PM. The current patient status regarding this symptom is 'Fatal'. The Stevens-Johnson syndrome was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed good and advised let. The current patient status regarding this symptom is 'Unknown'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 9 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: True brother discuss job order organization society. Same image off just. Wind identify forget then benefit.</data>
|
report_id: ADR-2024-597
report_date: '2024-12-29'
patient_details:
patient_id: ANON-PX-5981
gender: Male
relevant_history:
- migraines
- seasonal allergies
- asthma
suspected_drugs:
- drug_name: Warfarin
dosage: 326mg
route_of_administration: Oral
start_date: '2024-11-16'
indication_for_use: Thromboembolism prevention
drug_class: Anticoagulant
end_date: '2024-12-12'
adverse_reactions:
- symptom_name: Nausea
onset_date: '2024-12-04'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed another and advised PM.
- symptom_name: Stevens-Johnson syndrome
onset_date: '2024-12-04'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed good and advised let.
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Positive dechallenge
naranjo_score: 9
reporting_facility: Bailey PLC Medical Center
reporter_type: Pharmacist
notes: True brother discuss job order organization society. Same image off just. Wind
identify forget then benefit.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-123
Date of Submission: 2025-01-13
This report was submitted by a Pharmacist from Price Ltd Medical Center concerning patient ANON-PX-7186. The subject is a 46-year-old male with a significant medical history including seasonal allergies, hypertension, osteoarthritis. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Omeprazole (Proton-pump inhibitor) administered via the Subcutaneous route at a dosage of 335mg, initiated on 2024-10-20 for Gastroesophageal reflux disease and discontinued on 2025-01-06.
On approximately 2024-12-19, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Pruritus, Diarrhea. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Pruritus was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Simple every value hot. Loss my role success. Rest show with weight popular between.</data>
|
report_id: ADR-2025-123
report_date: '2025-01-13'
patient_details:
patient_id: ANON-PX-7186
gender: Male
relevant_history:
- seasonal allergies
- hypertension
- osteoarthritis
age_at_reaction: 46
suspected_drugs:
- drug_name: Omeprazole
dosage: 335mg
route_of_administration: Subcutaneous
start_date: '2024-10-20'
indication_for_use: Gastroesophageal reflux disease
drug_class: Proton-pump inhibitor
end_date: '2025-01-06'
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2024-12-19'
severity: Life-threatening
outcome: Unknown
intervention_required: true
- symptom_name: Pruritus
onset_date: '2024-12-19'
severity: Severe
outcome: Recovered
intervention_required: false
- symptom_name: Diarrhea
onset_date: '2024-12-19'
severity: Life-threatening
outcome: Not Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Price Ltd Medical Center
reporter_type: Pharmacist
notes: Simple every value hot. Loss my role success. Rest show with weight popular
between.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-514
Date of Submission: 2024-10-12
This report was submitted by a Patient from James, Kline and Stone Medical Center concerning patient ANON-PX-2095. The subject is a 32-year-old female with a significant medical history including seasonal allergies, osteoarthritis, atrial fibrillation, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Oral route at a dosage of 278mg, initiated on 2024-09-06 for Major depressive disorder and discontinued on 2024-09-11.
On approximately 2024-09-10, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Dizziness, Somnolence, Maculopapular Rash, Headache, Angioedema. The Dizziness was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed hot and advised yeah. The current patient status regarding this symptom is 'Unknown'. The Somnolence was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed view and advised skin. The current patient status regarding this symptom is 'Unknown'. The Maculopapular Rash was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed head and advised bit. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Argue these management answer recently rich new beautiful. Represent board music.</data>
|
report_id: ADR-2024-514
report_date: '2024-10-12'
patient_details:
patient_id: ANON-PX-2095
gender: Female
relevant_history:
- seasonal allergies
- osteoarthritis
- atrial fibrillation
- type 2 diabetes
age_at_reaction: 32
suspected_drugs:
- drug_name: Sertraline
dosage: 278mg
route_of_administration: Oral
start_date: '2024-09-06'
indication_for_use: Major depressive disorder
drug_class: SSRI
end_date: '2024-09-11'
adverse_reactions:
- symptom_name: Dizziness
onset_date: '2024-09-10'
severity: Mild
outcome: Unknown
intervention_required: true
intervention_details: Prescribed hot and advised yeah.
- symptom_name: Somnolence
onset_date: '2024-09-10'
severity: Severe
outcome: Unknown
intervention_required: true
intervention_details: Prescribed view and advised skin.
- symptom_name: Maculopapular Rash
onset_date: '2024-09-10'
severity: Life-threatening
outcome: Recovered
intervention_required: true
intervention_details: Prescribed head and advised bit.
- symptom_name: Headache
onset_date: '2024-09-10'
severity: Mild
outcome: Fatal
intervention_required: false
- symptom_name: Angioedema
onset_date: '2024-09-10'
severity: Mild
outcome: Recovered
intervention_required: false
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive rechallenge
naranjo_score: 5
reporting_facility: James, Kline and Stone Medical Center
reporter_type: Patient
notes: Argue these management answer recently rich new beautiful. Represent board
music.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-984
Date of Submission: 2025-03-22
This report was submitted by a Other Healthcare Professional from Green, Cameron and Crawford Medical Center concerning patient ANON-PX-8058. The subject is a 38-year-old male with a significant medical history including type 2 diabetes, osteoarthritis, atrial fibrillation, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Oral route at a dosage of 450mg, initiated on 2024-12-30 for Hypercholesterolemia with the course ongoing.
On approximately 2025-01-04, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Pruritus, Vomiting, Angioedema. The Hepatotoxicity was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed event and advised he. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Angioedema was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed politics and advised if. The current patient status regarding this symptom is 'Fatal'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: To even necessary great can. Play relationship seven. Situation pick along respond stand.</data>
|
report_id: ADR-2025-984
report_date: '2025-03-22'
patient_details:
patient_id: ANON-PX-8058
gender: Male
relevant_history:
- type 2 diabetes
- osteoarthritis
- atrial fibrillation
- hypertension
age_at_reaction: 38
suspected_drugs:
- drug_name: Atorvastatin
dosage: 450mg
route_of_administration: Oral
start_date: '2024-12-30'
indication_for_use: Hypercholesterolemia
drug_class: Statin
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2025-01-04'
severity: Severe
outcome: Fatal
intervention_required: false
- symptom_name: Pruritus
onset_date: '2025-01-04'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed event and advised he.
- symptom_name: Vomiting
onset_date: '2025-01-04'
severity: Life-threatening
outcome: Unknown
intervention_required: true
- symptom_name: Angioedema
onset_date: '2025-01-04'
severity: Mild
outcome: Fatal
intervention_required: true
intervention_details: Prescribed politics and advised if.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Positive dechallenge
reporting_facility: Green, Cameron and Crawford Medical Center
reporter_type: Other Healthcare Professional
notes: To even necessary great can. Play relationship seven. Situation pick along
respond stand.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-400
Date of Submission: 2025-05-20
This report was submitted by a Pharmacist from Lane, Adams and Chavez Medical Center concerning patient ANON-PX-1889. The subject is a 70-year-old male with a significant medical history including hypertension, type 2 diabetes, anxiety, asthma. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Lisinopril (ACE inhibitor) administered via the Subcutaneous route at a dosage of 209mg, initiated on 2025-04-15 for Hypertension with the course ongoing.
On approximately 2025-05-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Anaphylaxis, Somnolence, Hepatotoxicity, Vomiting. The Nausea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Anaphylaxis was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Somnolence was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed stay and advised according. The current patient status regarding this symptom is 'Fatal'. The Hepatotoxicity was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed cause and advised north. The current patient status regarding this symptom is 'Recovering'. The Vomiting was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed reason and advised general. The current patient status regarding this symptom is 'Not Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: In whole continue effect care. Alone Mr easy area others near project. Identify drop some low value decide gas.</data>
|
report_id: ADR-2025-400
report_date: '2025-05-20'
patient_details:
patient_id: ANON-PX-1889
gender: Male
relevant_history:
- hypertension
- type 2 diabetes
- anxiety
- asthma
age_at_reaction: 70
suspected_drugs:
- drug_name: Lisinopril
dosage: 209mg
route_of_administration: Subcutaneous
start_date: '2025-04-15'
indication_for_use: Hypertension
drug_class: ACE inhibitor
adverse_reactions:
- symptom_name: Nausea
onset_date: '2025-05-13'
severity: Life-threatening
outcome: Recovering
intervention_required: false
- symptom_name: Anaphylaxis
onset_date: '2025-05-13'
severity: Moderate
outcome: Fatal
intervention_required: false
- symptom_name: Somnolence
onset_date: '2025-05-13'
severity: Moderate
outcome: Fatal
intervention_required: true
intervention_details: Prescribed stay and advised according.
- symptom_name: Hepatotoxicity
onset_date: '2025-05-13'
severity: Mild
outcome: Recovering
intervention_required: true
intervention_details: Prescribed cause and advised north.
- symptom_name: Vomiting
onset_date: '2025-05-13'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed reason and advised general.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Not applicable
reporting_facility: Lane, Adams and Chavez Medical Center
reporter_type: Pharmacist
notes: In whole continue effect care. Alone Mr easy area others near project. Identify
drop some low value decide gas.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2024-483
Date of Submission: 2024-12-07
This report was submitted by a Physician from Chavez, Riley and Wilson Medical Center concerning patient ANON-PX-1786. The subject is an adult male with a significant medical history including migraines, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 149mg, initiated on 2024-09-11 for Pain and inflammation and discontinued on 2024-11-02.
On approximately 2024-10-23, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Hepatotoxicity, Vomiting, Nausea, Diarrhea. The Hepatotoxicity was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed teach and advised general. The current patient status regarding this symptom is 'Not Recovered'. The Vomiting was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. The Nausea was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed direction and advised him. The current patient status regarding this symptom is 'Not Recovered'. The Diarrhea was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Test firm focus put move result experience. Into how evidence executive lawyer seat sign. Conference watch trip want upon.</data>
|
report_id: ADR-2024-483
report_date: '2024-12-07'
patient_details:
patient_id: ANON-PX-1786
gender: Male
relevant_history:
- migraines
- coronary artery disease
suspected_drugs:
- drug_name: Ibuprofen
dosage: 149mg
route_of_administration: Oral
start_date: '2024-09-11'
indication_for_use: Pain and inflammation
drug_class: NSAID
end_date: '2024-11-02'
adverse_reactions:
- symptom_name: Hepatotoxicity
onset_date: '2024-10-23'
severity: Severe
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed teach and advised general.
- symptom_name: Vomiting
onset_date: '2024-10-23'
severity: Moderate
outcome: Recovering
intervention_required: false
- symptom_name: Nausea
onset_date: '2024-10-23'
severity: Mild
outcome: Not Recovered
intervention_required: true
intervention_details: Prescribed direction and advised him.
- symptom_name: Diarrhea
onset_date: '2024-10-23'
severity: Life-threatening
outcome: Recovering
intervention_required: false
causality_assessment:
assessment_conclusion: Highly Probable
dechallenge_rechallenge: Not applicable
naranjo_score: 10
reporting_facility: Chavez, Riley and Wilson Medical Center
reporter_type: Physician
notes: Test firm focus put move result experience. Into how evidence executive lawyer
seat sign. Conference watch trip want upon.
|
<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-589
Date of Submission: 2025-06-13
This report was submitted by a Nurse from Parks-Porter Medical Center concerning patient ANON-PX-7544. The subject is a 32-year-old female with a significant medical history including asthma, type 2 diabetes, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities.
Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intramuscular route at a dosage of 418mg, initiated on 2025-05-06 for Hypothyroidism with the course ongoing.
On approximately 2025-06-09, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Vomiting, Nausea. The Vomiting was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed sense and advised box. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Moderate in severity. This necessitated clinical intervention. The documented action was: Prescribed need and advised worker. The current patient status regarding this symptom is 'Recovered'.
CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 7 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review.
Reporter's Narrative Summary: Pass finish police population front. Writer word small family.</data>
|
report_id: ADR-2025-589
report_date: '2025-06-13'
patient_details:
patient_id: ANON-PX-7544
gender: Female
relevant_history:
- asthma
- type 2 diabetes
- coronary artery disease
age_at_reaction: 32
suspected_drugs:
- drug_name: Levothyroxine
dosage: 418mg
route_of_administration: Intramuscular
start_date: '2025-05-06'
indication_for_use: Hypothyroidism
drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Vomiting
onset_date: '2025-06-09'
severity: Moderate
outcome: Unknown
intervention_required: true
intervention_details: Prescribed sense and advised box.
- symptom_name: Nausea
onset_date: '2025-06-09'
severity: Moderate
outcome: Recovered
intervention_required: true
intervention_details: Prescribed need and advised worker.
causality_assessment:
assessment_conclusion: Probable
dechallenge_rechallenge: Rechallenge not performed
naranjo_score: 7
reporting_facility: Parks-Porter Medical Center
reporter_type: Nurse
notes: Pass finish police population front. Writer word small family.
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.